Page last updated: 2024-08-23

paclitaxel and Peritoneal Carcinomatosis

paclitaxel has been researched along with Peritoneal Carcinomatosis in 485 studies

Research

Studies (485)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's25 (5.15)18.2507
2000's167 (34.43)29.6817
2010's236 (48.66)24.3611
2020's57 (11.75)2.80

Authors

AuthorsStudies
Barraja, P; Carbone, A; Cirrincione, G; De Cesare, M; Diana, P; Doldi, V; Lopergolo, A; Montalbano, A; Parrino, B; Pennati, M; Sbarra, S; Spanò, V; Zaffaroni, N1
Barraja, P; Carbone, A; Cilibrasi, V; Cirrincione, G; Cominetti, D; Diana, P; Lopergolo, A; Montalbano, A; Parrino, B; Pennati, M; Spanò, V; Zaffaroni, N; Zuco, V1
Arai, H; Boku, N; Hara, H; Hyodo, I; Inoue, E; Muro, K; Nakajima, TE; Nakamura, S; Nishina, T; Sasako, M; Shinozaki, K; Shitara, K; Terashima, M; Tsuda, M; Yamaguchi, K1
Bixel, K; Brady, MF; Burger, RA; Casey, AC; Cosgrove, C; duPont, NC; Enserro, D; Fujiwara, K; Monk, BJ; Moxley, K; Rubin, S; Soper, J; Tewari, KS; Thaker, P; Wahner Hendrickson, AE; Walker, JL1
Feng, T; Li, C; Mei, Y; Shi, M; Yan, C; Yan, M; Yuan, H; Zhang, J; Zhu, Z1
Hiraki, Y; Imano, M; Kato, H; Momose, K; Nishida, S; Shinkai, M; Shiraishi, O; Tsubaki, M; Yasuda, A; Yasuda, T1
Chen, MM; Feng, RH; He, CY; Hua, ZC; Li, C; Liu, WT; Lu, S; Ni, ZT; Sah, BK; Wang, ZQ; Yan, C; Yan, M; Yang, ZY; Yao, XX; Zheng, YN; Zhu, ZG; Zhu, ZL1
Casas-Murillo, CA; González-Díaz, SN; López-Méndez, A; Santos-Fernández, WJ; Solís-Lara, H; Vidal-Gutiérrez, O; Villarreal-González, RV; Zayas-Villanueva, OA1
Fujii, T; Hashimoto, D; Hirano, S; Honda, G; Kitayama, J; Kodera, Y; Miura, F; Motoi, F; Satoi, S; Sekimoto, M; Shimokawa, T; Uemura, K; Ueno, H; Unno, M; Yamaki, S; Yamamoto, T; Yamaue, H; Yoshitomi, H1
Badau, LM; Ciocoiu, AD; Gheju, A; Oprean, CM; Segarceanu, NA; Vlaicu, B1
Sugarbaker, PH1
Bressler, E; Colson, YL; Ekladious, I; Grinstaff, MW; Hung, YP; Liu, R; Martin, A; Neal, EJ; Sabatelle, RC1
Fushimi, A; Higaki, K; Kono, Y; Ogawara, KI; Yoshizawa, Y1
Aerts, JGJV; Brandt-Kerkhof, ARM; Burger, JWA; Dietz, MV; Guchelaar, NAD; Koolen, SLW; Madsen, EVE; Mathijssen, RHJ; van Kooten, JP; Verhoef, C1
Ma, J; Zhang, S1
Enomoto, T; Fukuhara, S; Kamijima, S; Mandai, M; Ogino, K; Sugitani, Y; Ueda, A; Watari, H1
Baumann, K; Belau, A; Burges, A; Canzler, U; de Gregorio, N; Denschlag, D; El-Balat, A; Emons, G; Gropp-Meier, M; Hanker, LC; Harter, P; Hartkopf, AD; Hasenburg, A; Heubner, ML; Hilpert, F; Jackisch, C; Joly, F; Kristensen, G; Kurtz, JE; Lück, HJ; Mahner, S; Meier, W; Park-Simon, TW; Pautier, P; Pfisterer, J; Rau, J; Schmalfeldt, B; Schröder, W; Sehouli, J; Selle, F1
Bohart, RD; Goldstein, BH; Micha, JP; Rettenmaier, MA1
Hiraki, Y; Imano, M; Kato, H; Kimura, Y; Momose, K; Shinkai, M; Shiraishi, O; Teranishi, H; Yasuda, A; Yasuda, T1
Dayyani, F; Senthil, M1
Emoto, S; Gohda, Y; Ishigami, H; Ishihara, S; Kashiwabara, K; Kitayama, J; Matsuzaki, H; Murono, K; Nozawa, H; Sasaki, K; Yamaguchi, H; Yokoyama, Y1
Alban, LBV; Charruf, AZ; Dias, AR; Gregorio, JVAM; Hoff, PMG; Mello, ES; Moniz, CMV; Pereira, MA; Ramos, MFKP; Ribeiro Junior, U; Victor, CR; Zilberstein, B1
Au, JLS; Chan, CHF; Lu, Z; Turaga, K; Wientjes, MG1
Buckarma, E; Grotz, TE; Jin, Z; Thiels, CA1
Akagi, Y; Hashimoto, K; Hino, H; Horiuchi, H; Matono, S; Matsuo, T; Nagano, T; Shimomura, S; Sueyoshi, S; Uchida, S1
Blontzos, N; Iavazzo, C; Kalinoglou, N; Vafias, E; Vorgias, G1
Ishigami, H; Kanda, M; Kitayama, J; Kobayashi, D; Kodera, Y; Tanaka, C; Yamaguchi, H1
Goedken, M; Hatefi, A; Javidian, P; Louro, P; Malekshah, OM; Nomani, A; Patel, N; Polunas, M; Sarkar, S1
Jimi, T; Kaneda, M; Kitai, M; Matsuoka, K; Nagao, S; Shibutani, T; Shiozaki, T; Sudo, T; Suzuki, K; Yamaguchi, S; Yamamoto, K; Yano, H1
Aghajanian, C; Armstrong, DK; Bell-McGuinn, KM; Chen, A; Duska, LR; Fracasso, PM; Gordon, S; Gray, HJ; Guntupalli, SR; Hagemann, AR; Mathews, CA; Miller, A; Moore, KN; O'Cearbhaill, RE; O'Malley, D; Schilder, RJ; Walker, JL1
Awasthi, N; Hassan, MS; Li, J; Schwarz, MA; Schwarz, RE; von Holzen, U; Williams, F1
Iida, Y; Odajima, S; Okamoto, A; Saito, M; Tabata, J; Ueda, K; Yamada, K; Yanaihara, N; Yokomizo, R1
Chang, HK; Chang, SJ; Han, SS; Kim, DY; Kim, HS; Kim, J; Kim, S; Lee, JW; Lee, KH; Park, SJ; Park, SY; Shim, SH1
Ajani, J; Badgwell, B; Blum Murphy, M; Das, P; Estrella, J; Ikoma, N; Mansfield, P; Minsky, BD; Roy-Chowdhuri, S; Song, S; Wang, X1
Aieta, M; Chiriacò, G; Conca, R; Corona, SP; D'Angelo, A; Multari, AG; Paganini, G; Petrioli, R; Rosellini, P; Roviello, G1
Boku, N; Hara, H; Hyodo, I; Katayama, H; Mizusawa, J; Muro, K; Nakajima, TE; Nakamura, S; Nishina, T; Sakamoto, T; Shinozaki, K; Shitara, K; Terashima, M; Yamaguchi, K1
Burger, R; Coleman, RL; Handley, KF; Molin, GZD; Moore, KN; Sood, AK; Stagg, R1
Kubo, S; Tomita, N; Yamano, T1
Chang, SJ; Ji, YI; Kim, HS; Kim, JW; Kim, SY; Kwon, SH; Lee, EJ; Lee, M; Lee, SH; Lee, SJ; Park, S; Park, SJ; Roh, JW; Shim, SH; Song, T1
Emoto, S; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nozawa, H; Otani, K; Sasaki, K; Sonoda, H1
Stuart, OA; Sugarbaker, PH1
Eguchi, H; Goda, K; Hashimoto, Y; Ikeda, M; Imaoka, H; Kan, M; Kimura, G; Mitsunaga, S; Ohno, I; Otsuru, T; Sasaki, M; Suzuki, Y; Takahashi, H; Umemoto, K; Watanabe, K1
Fujii, T; Hayashi, M; Hirano, S; Inoue, H; Ishikawa, H; Kitayama, J; Kodera, Y; Motoi, F; Murakami, Y; Murotani, K; Satoi, S; Sekimoto, M; Shibuya, K; Sonohara, F; Takami, H; Yamada, S; Yamaki, S; Yamamoto, T; Yoshioka, I1
Bonney, GK; Charles, CJ; Cheow, ES; Chue, KM; Goh, BC; Jang, CJ; Kim, G; Li, RR; Looi, WD; Shabbir, A; So, JB; Sundar, R; Tai, CH; Tan, HL; Wang, L; Yong, WP1
Aghajanian, C; Banerjee, S; Berger, R; Boyd, AP; Christy-Bittel, J; Churruca, C; Cibula, D; Clamp, A; Coleman, RL; Colombo, N; Del Campo, JM; Drill, E; Grisham, RN; Hilpert, F; Kalbacher, E; Kristensen, G; Marth, C; Mirza, MR; Monk, BJ; Moore, KN; O'Malley, DM; Oehler, MK; Oza, AM; Pignata, S; Ray-Coquard, I; Romero, I; Sehouli, J; Vergote, I; Vuylsteke, P; Westermann, A1
Hayata, K; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H1
Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY1
Arai, H; Kawahira, M; Masuishi, T; Muro, K; Nakajima, TE; Yasui, H1
Arjona-Sanchez, A; Aziz, O; Briceño, J; Casado-Adam, A; Esquivel, J; Glehen, O; Nedelcut, DS; Passot, G; Piso, P; Rodriguez-Ortiz, L; Rufian-Peña, S; Salti, G; Sanchez-Hidalgo, JM; Selvasekar, CR; Sommariva, A; Turaga, K; Van der Speeten, K; Yonemura, Y1
Ishigami, H; Kitayama, J; Lefor, AK; Saito, S; Sata, N; Yamaguchi, H1
Hashimoto, Y; Hirahara, S; Kobayashi, H; Kubota, H; Kuhara, Y; Miyamoto, K; Sakashita, Y; Shirakawa, K; Toyota, K; Yano, R; Yokoyama, Y1
Akagi, S; Ando, H; Fujita, K; Ishida, T; Ishima, Y; Kusano, T; Matsushima, T; Shimizu, T; Tajima, K1
Irrinki, S; Kurdia, K; Yadav, T1
Fujii, T; Satoi, S; Yamada, S2
Chang, CS; Chiu, CC; Hsieh, MC; Pei, SN; Rau, KM; Tsai, YF1
Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y1
Fuyama, S; Higashi, T; Mase, K; Mizutani, M; Moriya, T; Ozawa, K; Takagi, S; Takei, S; Takeshita, A; Yokoyama, M1
Backes, FJ; Bixel, K; Chen, M; Cohn, DE; Copeland, LJ; Cosgrove, C; Dzwigalski, K; Fowler, JM; Hays, J; Hill, K; O'Malley, D; Phelps, M; Poi, M; Salani, R; Wei, L1
Ikeda, T; Kaneda, M; Kondo, E; Maki, S; Nii, M; Nimura, R; Tabata, T; Yoshida, K1
Azevedo, RB; Bonadio, RS; de Lima, LI; de Matos Neto, JN; de Oliveira, MC; Faria, RS; Longo, JPF; Moya, SE; Roque, MC1
Avallone, A; Capozzi, M; Cavalcanti, E; DE Divitiis, C; DI Girolamo, E; Nasti, G; Ottaiano, A; Romano, G; Tafuto, S; Tatangelo, F; VON Arx, C1
Enami, C; Hyodo, I; Iwai, K; Matano, D; Moriwaki, T; Nagase, M; Niisato, Y; Suganuma, D; Takagi Taketa, K; Tange, Y; Yamamoto, Y; Yamaura, M1
Armstrong, DK; Ashfaq, R; Basen-Engquist, K; Brady, MF; Chan, JK; Coleman, RL; Davidson, SA; DiSilvestro, P; Fujiwara, K; Herzog, TJ; Huang, H; Kim, BG; Mannel, RS; O'Malley, DM; Rubin, SC; Sabbatini, P; Spirtos, NM; Tewari, KS; Walker, JL1
Ishigami, H; Kitayama, J; Kurihara, M; Satoh, Y; Yamaguchi, H; Yatomi, Y1
Celebi, K; Kaban, A; Saip, P; Salihoglu, Y; Sozen, H; Topuz, S1
Aoki, D; Hashimoto, S; Hirano, T; Hirasawa, A; Iwasa, N; Kataoka, F; Makabe, T; Nanki, Y; Nomura, H; Sakai, K; Yamagami, W; Yoshihama, T1
Bun, S; Ebata, T; Fujiwara, Y; Kato, T; Kodaira, M; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yoshida, H; Yunokawa, M1
Espinosa Lara, P; Jiménez-Reyes, J; Medina-Puente, C; Riquelme Oliveira, A1
Barrios, P; Cascales-Campos, P; Esteve-Pérez, N; Morales-Soriano, R; Segura-Sampedro, JJ1
Misumi, T; Seo, S; Suzuki, T; Tashiro, H1
Hata, T; Hayashi, H; Iseki, M; Kanno, A; Kyakumoto, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Sakata, N; Shimosegawa, T; Takadate, T; Unno, M1
Bae, WK; Cherukula, K; Lee, JH; Park, IK1
Gao, J; Liu, Q; Qiu, N; Shen, Y; Wang, J1
Alessandro Peccatori, F; Bani, MR; Bizzaro, F; Colombo, N; D'Agostini, E; Decio, A; Erba, E; Falcetta, F; Giavazzi, R; Minoli, L; Scanziani, E; Ubezio, P; Zucchetti, M1
Becker, DA; Bevis, KS; Leath, CA; Smith, BQ; Walters-Haygood, CL1
Amagai, K; Boku, N; Chin, K; Choda, Y; Esaki, T; Fujii, H; Fujitani, K; Fukushima, N; Goto, M; Hara, H; Hara, T; Hironaka, S; Kimura, Y; Koeda, K; Koizumi, W; Machida, N; Morita, S; Muro, K; Nakayama, N; Nishikawa, K; Ohta, M; Sato, A; Shimura, M; Shitara, K; Takano, T; Takashima, A1
An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY1
Kruitwagen, RF; Lalisang, RI; Sonke, GS; Timmermans, M; Van de Vijver, KK; van der Aa, MA; Witteveen, PO1
Bodurka, DC; Bookman, MA; Friedlander, M; Geller, M; Glaser, G; Herzog, TJ; Java, JJ; Krivak, TC; Lee, RB; Mutch, DG; O'Malley, DM; Olawaiye, AB; Wenham, RM1
Chiba, Y; Hiraki, Y; Imano, M; Iwama, M; Kato, H; Kimura, Y; Nishida, S; Shinkai, M; Shiraisi, O; Tsubaki, M; Yasuda, A; Yasuda, T1
Chiba, Y; Hiraki, Y; Imano, M; Iwama, M; Kato, H; Kimura, Y; Nishida, S; Shinkai, M; Shiraishi, O; Tsubaki, M; Yasuda, A; Yasuda, T1
Aghajanian, C; Bonebrake, AJ; Dewdney, SB; Johnston, CM; Kauderer, JT; Monk, BJ; Moxley, KM; Secord, AA; Ueland, FR1
Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T1
Ishigami, H1
Ji, J; Li, Z; Xue, K; Ying, X1
Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E1
Aghajanian, C; Bender, DP; Carlson, JW; Crane, EK; Darus, CJ; Makker, V; Mannel, RS; Matulonis, UA; Mutch, DG; Sill, MW1
Aieta, M; Chiriacò, G; Conca, R; Multari, AG; Paganini, G; Petrioli, R; Rosellini, P; Roviello, G1
Akaishi, T; Hakamada, K; Hara, Y; Kubo, N; Mitsuhashi, Y; Muroya, T; Ogasawara, H; Sato, K; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yoshida, E; Yoshida, T1
Bakrin, N; Gladieff, L1
Kubo, T; Kuwata, T; Mihara, K; Ochiai, A; Seyama, T; Yanagihara, K; Yokozaki, H1
Alberca, A; Baladron, V; Estella, A; Faba, P; Fernandez, E; Fernández, J; Marta, P; Martín, J; Montenegro, O; Oyarzabal, J; Padilla-Valverde, D; Palomino, T; Redondo, J; Sanchez, S; Villarejo, P1
Amano, S; Goto, A; Hanai, T; Hattori, Y; Inaba, K; Kadoya, S; Kato, Y; Kikuchi, K; Nakamura, K; Nakauchi, M; Sugioka, A; Tomatsu, M; Tsuru, Y; Uyama, I1
Calzas, J; Carrión, L; Manzanedo, I; Martínez-Torres, B; Pereira, F; Pérez-Viejo, E; Serrano, Á1
Chang, CW; Chen, CH; Cheng, CJ; Chiu, YH; Fu, HS; Liu, WM; Wang, ID; Wu, YC1
Akladios, C; Alfonsi, P; Bakrin, N; Ballester, M; Bendifallah, S; Bolze, PA; Bonnet, F; Bourgin, C; Chabbert-Buffet, N; Collinet, P; Courbiere, B; Daraï, E; De la Motte Rouge, T; Devouassoux-Shisheboran, M; Falandry, C; Ferron, G; Fournier, L; Gladieff, L; Golfier, F; Gouy, S; Guyon, F; Huchon, C; Lambaudie, E; Lavoue, V; Leary, A; Leblanc, E; Lecuru, F; Lefrere-Belda, MA; Lemoine, A; Narducci, F; Ouldamer, L; Pautier, P; Planchamp, F; Pouget, N; Ray-Coquard, I; Rousset-Jablonski, C; Senechal-Davin, C; Thomassin-Naggara, I; Touboul, C; Uzan, C; You, B1
Bamias, A; Colombo, N; Covens, A; Del Campo, JM; Kroep, JR; Ma, H; Marth, C; Meier, W; Monk, BJ; O'Malley, DM; Park, SY; Pickett, CA; Raza Mirza, M; Scambia, G; Van Calster, B; Vergote, I; Wenham, RM1
Amiji, MM; Menon, D; Nair, SV; Padmakumar, S; Parayath, NN1
Hirose, Y; Ishii, A; Ishimoto, U; Iwaku, A; Kinoshita, A; Koike, K; Mizuno, Y; Saruta, M; Shibata, K; Shoji, R; Yokota, T1
Baratti, D; Deraco, M; Guaglio, M; Kusamura, S; Nizri, E; Rajendra, VJ; Salcedo-Hernández, RA; Sinukumar, S1
Aoki, M; Boku, N; Hirano, H; Honma, Y; Imazeki, H; Ishikawa, M; Iwasa, S; Kato, K; Nagashima, K; Okita, N; Saruta, M; Shoji, H; Takashima, A1
Blaakaer, J; Christiansen, T; Iversen, LH; Mikkelsen, MS; Petersen, LK1
Kaye, SB; Kipps, E; Tan, DS1
Mutasim, DF; Spicknall, KE1
Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ1
Apte, SM; Bou Zgheib, N; Gonzalez-Bosquet, J; Judson, PL; Lancaster, JM; Roberts, WS; Teefey, P; Wenham, RM1
Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Mendivil, AA; Micha, JP; Rettenmaier, MA2
Imano, M; Okuno, K1
Dhillon, S1
Goto, S; Kamigaki, T; Saito, M; Yano, K1
Emoto, S; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H1
Katayama, K; Nishino, T; Okitsu, H; Okitsu, N; Takahashi, Y; Tanaka, T1
Bookman, MA; Brady, MF; Burger, RA; Kong, G; Nguyen, HP; Rhee, J; Sovak, MA1
Aoki, D; Isonishi, S; Jobo, T; Katsumata, N; Kimura, E; Kodama, S; Michimae, H; Ochiai, K; Sugiyama, T; Takahashi, F; Terauchi, F; Yasuda, M1
Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H1
Fujiwara, K; Iwasaki, S; Muraji, M; Nishimura, R; Sudo, T; Ueno, S; Wakahashi, S; Yamaguchi, S1
Enomoto, N; Hamaguchi, T; Honma, Y; Iwasa, S; Kadokura, M; Kato, K; Shimada, Y; Yamada, Y1
Chen, W; Li, H; Tong, L; Wu, J1
Cho, H; Fujikawa, H; Iwasaki, K; Kasahara, A; Masuda, M; Ogata, T; Osaragi, T; Rino, Y; Shirai, J; Sujishi, K; Tsuburaya, A; Yamada, T; Yamamoto, Y; Yoneyama, K; Yoshikawa, T1
Ebisui, C; Fukuchi, N; Kato, R; Kinuta, M; Makino, S; Murata, K; Okada, K; Okamura, S; Takeoka, T; Wada, Y; Yanagisawa, T; Yokouchi, H1
Akita, H; Fujiwara, Y; Gotoh, K; Ishigami, H; Kishi, K; Kitayama, J; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Sakon, M; Sasaki, K; Sugimura, K; Takahashi, H; Yano, M1
Araki, T; Ide, S; Inoue, Y; Kitajima, T; Kondo, S; Kusunoki, M; Mizoguchi, A; Mohri, Y; Ohi, M; Okigami, M; Saigusa, S; Shimura, T; Tanaka, K; Toiyama, Y; Uchida, K1
Goto, Y; Kato, H; Matano, Y; Nishino, A; Tsukayama, S; Yoshimitsu, M1
Awtrey, CS; Battelli, C; Buss, MK; Campo, M; Konstantinopoulos, PA1
Au, JL; Cole, DJ; Lu, Z; Wang, J; Wientjes, MG; Yeung, BZ1
Emoto, S; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H2
González Ruiz de la Herrán, F; Haya Palazuelo, J; López de la Manzanara Cano, C; Martín Fernández, J; Padilla Valverde, D; Pascual-Ramírez, J; Sánchez García, S; Villarejo Campos, P1
García-Rojo, M; Martín-Fernández, J; Padilla-Valverde, D; Rodríguez-Martínez, M; Sánchez-García, S; Villarejo-Campos, P1
Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ1
Bookman, MA; Gatcliffe, TA; Java, JJ; Monk, BJ; Tewari, KS1
Baranowski, W; Bodnar, L; Cichowicz, M; Cierniak, S; Dąbek, A; Gąsowska-Bodnar, A; Jerzak, M; Kozłowski, W1
Aisu, N; Hoshino, S; Maki, K; Naito, M; Nakagawa, M; Yamashita, Y; Yoshida, Y1
Boussery, K; Ceelen, W; Colin, P; De Smet, L; Remon, JP; Van Bocxlaer, J; Vermeulen, A; Vervaet, C1
Fujimura, T; Furukawa, H; Fushida, S; Hayashi, H; Hirakawa, K; Inokuchi, M; Kinoshita, J; Makino, I; Masakazu, Y; Miyashita, T; Nakagawara, H; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Shoji, M; Tajima, H; Takamura, H; Tsukada, T; Watanabe, T1
Aktas, B; Alici, S; Aslan, K; Buyukberber, S; Cinkir, HY; Demirci, U; Günaydın, Y; Inal, A; Oksuzoglu, B; Ozatli, T; Oztop, I; Unal, OU; Uncu, D; Yazici, O; Yilmaz, AU1
Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q1
Hirano, M; Ichinose, M; Mizumoto, A; Ozamoto, Y; Takao, N; Tatsuno, M; Togawa, T; Yamamoto, Y; Yonemura, Y1
Cascales-Campos, PA; Feliciangeli, E; Gil, E; Gil, J; González-Gil, A; López, V; Nieto, A; Parrilla, JJ; Parrilla, P; Ruiz-Pardo, J1
Arjona-Sánchez, A; Briceño Delgado, J; Casado-Adam, A; Garcilazo Arismendi, DJ; Gómez-Luque, I; Medina Fernández, FJ; Muñoz-Casares, FC; Rufián Peña, S; Thoelecke, H1
Baidoo, KE; Brechbiel, MW; Milenic, DE; Yong, KJ1
Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ1
Becker, HG1
Chevreau, C; Culine, S; Delva, R; Eymard, JC; Fizazi, K; Fléchon, A; Geoffrois, L; Gravis, G; Habibian, M; Journeau, F; Kerbrat, P; Laplanche, A; Linassier, C; Logothetis, C; Malhaire, JP; Mardiak, J; Martin, AL; Pagliaro, L; Reckova, M; Rolland, F; Roubaud, G; Theodore, C1
Ansaloni, L; Ballerini, A; Bertoli, P; Busci, LM; Cambria, F; Ceresoli, M; Coccolini, F; D'Incalci, M; Frigerio, L; Grosso, G; Lotti, M; Morosi, L; Pisano, M; Rossetti, D; Zucchetti, M1
Sánchez-García, S1
Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P1
Akita, H; Hayasaka, J; Kondo, M; Kusano-Kitazume, A; Ohtaka, Y; Okamoto, E; Shibayama, T; Suenobu, Y; Takagi, K; Tamura, A; Tei, S; Watanabe, A1
Fujii, K; Iwai, N; Kataoka, K; Masuzawa, A; Matsumoto, N; Morita, Y; Takada, R; Takami, S; Takaya, H; Tanaka, N; Wakabayashi, N; Yoriki, H1
Katsumata, N1
Fukuda, T; Hashiguchi, Y; Ichimura, T; Imai, K; Sumi, T; Teramae, M; Yamauchi, M; Yasui, T1
Baltezor, MJ; Decedue, CJ; diZerega, GS; Espinosa, J; Johnson, GA; Mackay, CB; Markman, M; Maulhardt, HA; McMeekin, DS; Moore, KM; Reed, GA; Roby, KF; Schulz, TK; Smith, HJ; Weir, SJ; Wick, JA; Williamson, SK1
Emoto, S; Hanafusa, N; Ishigami, H; Ito, T; Kitayama, J; Watanabe, T; Yamaguchi, H1
Aramendía, JM; D'Amelio, CM; Fusco, JP; Gastaminza, G; Goikoetxea, MJ; Yuste, JR1
Au, JL; Lu, Z; Wientjes, MG1
Cozma, A; Muntean, V; Simescu, R; Şimon, I; Togănel, RD; Zolog, A1
Dartigues, P1
Au, JL; Cole, DJ; Cui, M; Lu, Z; Wang, J; Wientjes, MG; Yeung, BZ1
Alexander, H; Banerjee, S; Barton, D; Bodla, S; Georgiou, A; Gore, M; Kaye, S; McLachlan, J; Nobbenhuis, M; Seifert, H1
Burger, RA; Cohn, DE; Duska, LR; Java, JJ1
Fushida, S; Hayashi, H; Hirakawa, K; Kinoshita, J; Miyashita, T; Ninomiya, I; Ohbatake, Y; Ohta, T; Oyama, K; Tajima, H; Takamura, H; Tsukada, T; Yashiro, M1
Amagai, K; Boku, N; Gotoh, M; Hamamoto, Y; Kawai, H; Mizusawa, J; Nakamura, K; Nakayama, N; Nishina, T; Ohtsu, A; Shimada, Y; Shirao, K; Yamaguchi, K; Yasui, H1
Zhu, Z1
Alexandrov, VA; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Kireeva, GS; Kopteva, OS; Krasilnikova, LA; Maidin, MA; Semenov, AL; Stukov, AN; Vasilieva, IN; Vyshinskaya, EA1
Bidziński, M; Bjørge, L; Colombo, N; de Gregorio, N; Del Campo, JM; Denison, U; du Bois, A; Harter, P; Heubner, M; Hilpert, F; Kristensen, G; Lortholary, A; Malander, S; Meier, W; Merger, M; Minarik, T; Mirza, MR; Nicoletto, MO; Ottevanger, P; Pfisterer, J; Pignata, S; Ray-Coquard, I; Reuss, A; Sailer, MO; Scambia, G; Sevin, E; Vergote, I1
Arjona-Sánchez, Á; Briceño, FJ; Casado-Adam, Á; Medina-Fernández, FJ; Muñoz-Casares, FC; Muñoz-Villanueva, MC; Ortega-Salas, R; Rubio, MJ; Rufián-Peña, S; Sánchez-Hidalgo, JM1
Cao, Y; Gao, J; Gong, J; Li, Y; Lu, Z; Shen, L; Zhang, Q1
Emoto, S; Hata, K; Ishigami, H; Ishihara, S; Kawai, K; Kazama, S; Kitayama, J; Kiyomatsu, T; Nishikawa, T; Nozawa, H; Sunami, E; Tanaka, J; Tanaka, T; Watanabe, T; Yamaguchi, H1
Fukunari, H; Hayashi, T; Kato, T; Nakao, K; Okajima, C; Shitara, K; Watanabe, G; Yamamoto, Y1
Arimitsu, H; Chibana, T; Ikeda, A; Imanishi, S; Ishige, F; Kainuma, O; Kobayashi, R; Nabeya, Y; Sasaki, K; Souda, H; Takiguchi, N; Tonooka, T; Yamamoto, H1
Akita, H; Fujiwara, Y; Gotoh, K; Kobayashi, S; Miyata, H; Miyoshi, N; Noura, S; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M1
Amano, H; Fukuda, T; Kawashima, M; Nakahara, M; Noriyuki, T; Ono, N; Saito, R; Sasada, T; Takei, D; Takemoto, Y; Yamaki, M; Yoshida, M1
Chia, CS; Ong, WS; Soo, KC; Tan, GH; Teo, MC; Tham, CK1
Battaglia, G; Braun, GB; Gaitzsch, J; Hunt, H; Ruoslahti, E; Scodeller, PD; Simón-Gracia, L; Teesalu, T; Willmore, AM1
Ji, ZH; Li, Y; Peng, KW; Sun, JH; Wu, HT; Yonemura, Y; Zhang, Q1
Amo-Salas, M; Martín-Fernández, J; Padilla-Valverde, D; Sánchez-García, S; Villarejo-Campos, P1
Kakiuchi, Y; Takashima, H; Urano, S1
Chaithongwongwatthana, S; Yanaranop, M1
Awasthi, N; Grojean, M; Monahan, S; Schwarz, MA; Schwarz, RE; Scire, E; Zhang, E1
Chang, WP; Chang, Y; Chang, YH; Chuang, CM; Lee, WH; Lu, CH; Yen, MS1
Akkar, OB; Karadayi, K; Karakus, S; Kurt, A; Ugurlu, GP; Yanik, A; Yildiz, C1
Deng, L; Dong, A; Fan, H; Tang, H; Xu, S; Yin, L; Zhang, J1
Chi, DS; Gardner, GJ; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Schlappe, BA; Sonoda, Y; Zivanovic, O1
Achilefu, S; Betts, D; Bui, K; Cho, H; Kwon, GS; Liang, K; McKenzie, M; Suh, A; Tang, R1
Kamura, T; Kasamatsu, T; Kawana, K; Kobayashi, H; Konishi, I; Nakamura, K; Nakanishi, T; Onda, T; Saito, M; Saito, T; Satoh, T; Takano, M; Takehara, K; Takeshima, N; Ushijima, K; Wakabayashi, M; Watanabe, Y; Yaegashi, N; Yokota, H; Yoshikawa, H1
Colby, AH; Colson, YL; Gilmore, D; Grinstaff, MW; Liu, R; Padera, RF; Schulz, M; Shirihai, O; Zeng, J1
Bun, S; Ebata, T; Fujiwara, Y; Hayashi, Y; Kato, T; Kodaira, M; Makino, Y; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M1
Arévalo-Pérez, J; Barceló, F; Cascales-Campos, P; Gil, E; Gil, J; López-López, V; Nieto, A; Parrilla, P1
Deme, D; Telekes, A1
Bamias, A; Chmielowska, E; Colombo, N; Davidenko, I; DeCensi, A; Gadducci, A; González-Martín, A; Hegg, R; Joly, F; Korach, J; Martin, N; Mendiola, C; Oza, AM; Pautier, P; Robb, S; Selle, F; Zamagni, C; Zvirbule, Z1
Bun, S; Ebata, T; Fujiwara, Y; Kato, T; Kodaira, M; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M1
Chereau, E; Colombo, PE; Cottu, P; Dupin, J; Fauvet, R; Floquet, A; Follana, P; Fourchotte, V; Ghazi, Y; Gouy, S; Joly, F; Kalbacher, E; Lambaudie, E; Lecuru, F; Lesoin, A; Martin-Francoise, S; Pomel, C; Rouzier, R; Selle, F; Zohar, S1
Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP1
Asakage, M; Ishigami, H; Kitayama, J; Yamaguchi, H; Yamashita, H1
Fujii, T; Honda, G; Isayama, H; Ishigami, H; Kodera, Y; Kon, M; Kurata, M; Mizuma, M; Motoi, F; Satoi, S; Takahara, N; Unno, M; Yamada, S; Yamamoto, T; Yanagimoto, H1
Fujimura, Y; Iwata, M; Kato, K; Maeda, K; Moriyama, T; Ohsawa, I; Sakamoto, T; Sanda, T; Tabata, M1
Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC1
Chang, D; Sugarbaker, PH1
Awasthi, N; Hassan, MS; Li, J; Schwarz, MA; Schwarz, RE; von Holzen, U1
Acocella, F; Ansaloni, L; Brizzola, S; Ceresoli, M; Coccolini, F; D'Incalci, M; Davoli, E; Ghiringhelli, M; Morosi, L; Zucchetti, M1
Baekelandt, MM; Dugan, MH; Fracasso, PM; Gordon, AN; Joly, F; Jones, GJ; Lhommé, C; Lissoni, AA; Manikhas, GM; Mietlowski, WL; Nicoletto, MO; Walker, JL1
Aghajanian, CA; DeRosa, FA; Gerst, SR; Hensley, ML; Konner, J; Sabbatini, PJ; Schilder, RJ; Spriggs, DR; Tew, WP1
Aikins, JK; Allievi, C; Bookman, MA; Darcy, KM; DeGeest, K; Egorin, MJ; Mannel, RS; Morgan, MA; Rose, PG; Sill, MW1
Saitou, T; Sasaki, H; Tokunaga, Y1
Kaminishi, M; Shimoyama, S1
Albert, PS; Baidoo, KE; Brady, ED; Brechbiel, MW; Flynn, J; Garmestani, K; Milenic, DE; Wong, KJ1
Abu-Rustum, NR; Bains, M; Huang, M; Levine, DA; Rizk, N1
Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Takahashi, K; Tsuno, NH; Yamada, J; Yamashita, H1
Ikeguchi, M; Inoue, M; Matsumoto, S; Saito, H; Tsujitani, S1
Adler, L; O'Malley, D; Sabbatini, P; Secord, AA; Sill, MW1
Boterberg, T; Bouquet, W; Bracke, M; Ceelen, W; Pattyn, P; Peeters, M; Remon, JP; Vervaet, C1
Atkinson, T; Horowitz, NS; Krag, KJ; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT1
Gao, M; Gao, YN; Jiang, GQ; Wang, W; Yan, X; Zheng, H1
Miki, H; Miyake, T; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Yoshimura, M1
Alberts, DS; Liu, PY; Markman, M; Robinson, WR; Smith, HO; Tiersten, AD; Wilczynski, SP1
Fukuda, H; Hatae, M; Iwasaka, T; Kamura, T; Kobayashi, H; Konishi, I; Nakanishi, T; Onda, T; Shibata, T; Yoshikawa, H1
Alvarez, RD; Berry, E; Buttin, BM; Lurain, JR; Matthews, KS; Schink, J; Singh, DK1
Chauffert, B; Combe, M; Delroeux, D; Demarchi, M; Guardiola, E; Heyd, B; Lorgis, V; Pivot, X; Royer, B; Stein, U1
Accario-Winslow, C; Alberts, DS; Argenta, PA; Bookman, MA; Brady, MF; Burger, RA; Colombo, N; De Geest, K; Fowler, JM; Friedlander, M; Harper, PG; McGuire, WP; Mutch, DG; Roth, LM; Swart, AM; Trimble, EL1
Asmar, L; Boehm, KA; Crozier, M; Encarnacion, C; Hancock, K; Messing, MJ; Teneriello, MG; Tseng, PC; Williams, A1
Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H1
Banz, C; Diedrich, K; Hornung, D; Noack, F; von Otte, S1
Ando, T; Furuta, R; Goto, H; Ina, K; Kataoka, T; Kayukawa, S; Masaki, A; Nagao, S; Nishio, T1
Argenta, PA; Geller, M; Ivy, JJ; Jonson, AL; Pierson, SM1
Akamatsu, N; Aotani, E; Fujiwara, K; Kigawa, J; Miyagi, Y; Nagao, S; Noma, J; Numa, F; Okada, M1
Ishigami, H; Ishihara, K; Kaisaki, S; Kamei, T; Kitayama, J; Konno, T; Nagawa, H; Soma, D; Yamada, J1
Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H2
Ito, C; Kamijo, Y; Miyamoto, K; Nomura, M; Sai, Y1
Fushida, S; Kimura, H; Mukawa, A1
Alboni, C; Bernardi, A; Cacciari, N; Capizzi, E; D'Errico Grigioni, A; De Iaco, P; Denkert, C; Dietel, M; Martoni, AA; Massari, F; Quercia, S; Rosati, F; Rosati, M; Sehouli, J; Veltrup, E; Wirtz, RM; Zamagni, C1
Hoekstra, AV; Hurteau, JA; Kirschner, CV; Rodriguez, GC1
Ikeda, H; Kanagawa, T; Katoh, H; Kobayashi, K; Kodera, M; Oishi, M; Seshimo, K; Takita, K; Yamamura, M; Yamashita, Y; Yokomichi, N1
Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Sood, AK1
Bender, GP; Masellis, AM; Sielaff, TD1
Amant, F; Bauknecht, T; Darstein, C; Kania, M; Michel, AL; Musib, L; Oskay-Oezcelik, G; Sehouli, J; Vergote, I1
Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C1
Fujimura, T; Fujita, H; Fushida, S; Harada, S; Hirakawa, K; Kayahara, M; Kinoshita, J; Kinuya, S; Ninomiya, I; Ohta, T; Oyama, K; Tsukada, T; Yagi, Y; Yashiro, M1
Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M; Yoshioka, Y1
Asami, S; Hirata, M; Idani, H; Kin, H; Kubo, S; Kumano, K; Kurose, Y; Muro, M; Nojima, H; Sasaki, H; Takakura, N; Yamashita, T; Yoshioka, T1
Fujitani, K; Furukawa, H; Kimura, Y; Machida, H; Shimokawa, T; Takiuchi, H; Tominaga, K; Tsujinaka, T; Yamamoto, M; Yano, H1
Bougnoux, P; Carrasco, AT; Fumoleau, P; Joly, F; Kerbrat, P; Lhommé, C; Pautier, P; Petit, T; Ringeisen, F; Rixe, O1
Adachi, T; Hatoh, T; Matsui, K; Oshita, H; Tanemura, H; Yamada, M1
Jensen, S; Krarup-Hansen, A; Pedersen, JV; Riis, L1
Chu, P; Ghatage, P; Lucero, CA; Nation, J; Nelson, G1
Fracasso, PM; Garcia, AA; Knight, D; Mannel, RS; Muggia, F; Sill, MW; Swensen, R; Tiersten, AD; Warshal, DP1
Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Takeno, A; Tamura, S; Uji, K; Yoshida, A1
Boku, N; Fukutomi, A; Kojima, T; Machida, N; Onozawa, Y; Shukuya, T; Taku, K; Yamazaki, K; Yasui, H1
Han, TS; Hur, K; Kim, WH; Kwak, MK; Lee, HJ; Song, SC; Yanagihara, K; Yang, HK; Yu, J1
Keating, JP; Kenwright, DN; Saluja, M1
Blank, SV; Chen, HX; Christos, P; Curtin, JP; Goldman, N; Liebes, L; Muggia, FM; Runowicz, CD; Sparano, JA1
Chua, TC; Deraco, M; Glehen, O; Moran, BJ; Sugarbaker, PH; Yan, TD1
Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK1
Aoki, D; Aotani, E; Fujiwara, K; Hamano, T; Katsumata, N; Kigawa, J; Nagao, S; Sugiyama, T; Suzuki, M; Takeuchi, M; Yoshikawa, H1
Emoto, S; Ishigami, H; Ishihara, K; Kaisaki, S; Kamei, T; Kitayama, J; Konno, T; Nagawa, H; Soma, D; Yamaguchi, H1
Imano, M; Kodera, Y; Miyashita, Y; Morita, S; Nakao, A; Sakamoto, J; Sasako, M; Takahashi, N; Tsuburaya, A; Yoshikawa, T1
Colson, YL; Grinstaff, MW; Griset, AP; Liu, R; Padera, RF; Schulz, MD; Southard, EB; Wade, JE; Zubris, KA1
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK1
Ishikawa, M; Komiyama, M; Komiyama, S; Kurahashi, T; Mikami, M; Tanaka, K; Udagawa, Y1
Coleman, RL; Degeest, K; Fujiwara, K; Greer, B; Mannel, RS; Morgan, MA; Rubin, SC; Sill, MW; Waggoner, S; Walker, JL; Yamada, SD1
Balthasar, JP; Bernacki, RJ; Shah, DK; Veith, J1
Shoji, T1
Higashijima, J; Iwata, T; Kurita, N; Miyatani, T; Morimoto, S; Nakao, T; Nishioka, M; Shimada, M; Yoshikawa, K1
Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Nagawa, H; Yamaguchi, H; Yamashita, H1
Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T1
Brantley, E; Fidler, IJ; He, J; Kim, JS; Kim, SJ; Kim, SW; Lehembre, F; Maya, M; Regenass, U; Wu, Q; Yun, SJ; Zhang, F1
Azodi, M; Baker, L; Husband, A; Kelly, MG; Mor, G; O'Malley, DM; Rutherford, TJ; Schwartz, PE1
Bouquet, W; Ceelen, WP; De Smet, L; De Vos, F; Debergh, I; Deleye, S; Remon, JP; Staelens, S; Van Damme, N; Vervaet, C1
Lentz, S; Levine, EA; Parson, EN; Russell, G; Shen, P; Stewart, JH1
Arjona-Sánchez, Á; Casado-Adam, Á; Díaz-Nieto, R; Muñoz-Casares, FC; Ortega-Salas, R; Rubio-Pérez, MJ; Rufián-Peña, S1
Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Micha, JP; Rettenmaier, MA1
Blessing, JA; McMeekin, S; Miller, DS; Muller, CY; Rotmensch, J; Schilder, RJ; Shahin, MS; Tewari, KS; Warshal, DP1
Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C1
Brady, WE; Coleman, RL; Hoffman, JS; Lentz, SS; McMeekin, DS; Rose, PG; Shahin, MS; Soper, JT1
Aranda, E; Arjona-Sánchez, Á; Casado, Á; Díaz, R; Díaz-Iglesias, CJ; Muñoz-Casares, FC; Muñoz-Villanueva, MC; Muntané, J; Naranjo, Á; Ortega, R; Rubio, MJ; Rufián, S1
Oehler, MK; Ricciardelli, C; Ween, MP1
Berrada, N; Errihani, H; Jalil, A; Kettani, F; Mrabti, H; Zakkouri, FA1
Hyde, J; Landrum, LM; Mannel, RS; McMeekin, DS; Moore, KN; Walker, JL1
Hayes, JH; Ho, VT; Hornick, JL; Jagannathan, JP; O'Regan, KN; Ramaiya, N; Sneag, DB1
An, X; He, Y; Li, Y; Wang, F; Wang, Z; Xu, R; Zhou, N1
Debernardo, RL; Dizon, DS; Duska, LR; Eisenhauer, EL; Fracasso, PM; Gould, N; Mannel, RS; Rubin, SC; Sill, MW; Yamada, SD1
Fujiwara, K; Kimoto, T; Maeda, T; Makino, T; Nishida, Y; Nomura, Y; Sakata, Y; Tada, H; Takeuchi, N; Ueno, S1
Imamoto, H; Imano, M; Itoh, T; Kato, H; Okuno, K; Peng, YF; Satou, T; Shinkai, M; Shiozaki, H; Shiraishi, O; Takeyama, Y; Yasuda, A; Yasuda, T1
Chen, RC; Copp, JA; Cummings, ND; Karve, S; Sukumar, R; Wang, AZ; Werner, ME; Zhang, T1
Dohi, S; Inoue, M; Kyo, S; Ohno, S; Ohno, Y; Soma, G; Sugiyama, H; Takakura, M1
Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM1
Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L1
Ota, T; Takeshima, N; Takizawa, K1
Fujiwara, K; Goto, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T; Ohishi, R1
Armstrong, DK; Disilvestro, P; Fracasso, PM; Gould, N; Huang, H; Mannel, RS; Sill, MW; Thaker, PH; Waggoner, S; Walker, JL; Wenzel, L; Yamada, SD1
Brown, JV; Buck, M; Chambers, SK; Covens, A; Davy, M; Ghatage, P; Hansen, VL; Karlan, BY; Leath, CA; Nagarkar, RV; Nguyen, H; Oza, AM; Pippitt, CH; Provencher, DM; Richardson, GE; Stepan, DE; Sun, YN; Tassoudji, M; Vergote, IB; Weinreich, DM1
Ishikawa, H; Iwazaki, S; Izumi, M; Kakinuma, S; Kamoshita, N; Kawate, S; Kobayashi, I; Kobayashi, J; Makita, F; Nakagami, K; Ohya, T; Okabe, T; Sakamoto, I; Sato, Y; Sunose, Y; Takeyoshi, I; Tanahashi, Y; Tomizawa, N; Yamada, T; Yoshinari, D1
Brenton, JD; Crawford, RA; Earl, HM; Gill, AB; Graves, MJ; Griffiths, JR; Hodgkin, C; Jimenez-Linan, M; Joubert, I; Kataoka, MY; Lomas, DJ; McLean, MA; Priest, AN; Sala, E1
Itamochi, H; Kigawa, J; Kitada, F; Minagawa, Y; Okada, M; Sato, S; Shimada, M1
Aiba, T; Furukawa, K; Hayashi, M; Igarashi, K; Sato, M; Shibuya, H; Sugimura, K; Waguri, N; Yoneyama, O1
Abu Shahin, N; Alberts, DS; Chambers, SK; Chow, HH; Clouser, MC; Cohen, JL; Cragun, JM; Cui, H; Hatch, KD; Janicek, MF; Laughren, C; Wright, HM1
Gallagher, CJ; Jeyarajah, A; Ledermann, JA; McCormack, M; McDonald, N; McNeish, I; Mould, T; Olaitan, A; Oram, D; Orphanos, G; Reynolds, K; Saha, A; Shepherd, J; Varughese, M; Wilson, P1
Li, H; Tong, X; Wang, J; Yang, F1
Aghajanian, C; Barlin, JN; Bell-McGuinn, KM; Bou Zgheib, N; Chi, DS; Dao, F; Ferguson, SE; Hensley, ML; Konner, J; Sabbatini, PJ; Tew, WP1
Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tan, T; Tani, S1
Agaimy, A; Besendörfer, M; Brecht, IB; Carbon, R; Holter, W; Langer, T; Metzler, M; Osinski, D; Rompel, O; Thiel, FC1
Gong, C; Luo, F; Qian, Z; Wang, C; Wang, Y; Wu, Q; Zhang, D1
Bracke, M; Ceelen, W; Colin, P; De Smet, L; Remon, JP; Van Bocxlaer, J; Vervaet, C1
Agnoletti, V; Amadori, A; Ansaloni, L; Catena, F; Cavaliere, D; Coccolini, F; De Iaco, P; Di Battista, M; Framarini, M; Gazzotti, F; Ghermandi, C; Kopf, B; Pinna, AD; Saponara, M; Tauceri, F; Vallicelli, C; Verdecchia, GM1
Fortier, AH; Fu, S; Hong, DS; Kurzrock, R; Lim, J; Naing, A; Subbiah, IM; Tsimberidou, AM; Wen, S1
Bristow, RE; Chang, SJ; Ryu, HS1
Campos, S; Esselen, KM; Growdon, W; Horowitz, NS; Krasner, C; Rodriguez, N1
Fuse, N; Goto, M; Hironaka, S; Iwasa, S; Kusaba, H; Nakajima, TE; Nakayama, N; Nishina, T; Shimada, Y; Taira, K; Takahari, D; Yasui, H1
Goto, M; Hirata, Y; Kawahara, Y; Kitamura, M; Nakayama, M; Ohta, R; Oneyama, M; Sekikawa, K; Shimoda, Y; Takahashi, Y1
Fujiwara, Y; Furukawa, K; Haruki, K; Iwase, R; Misawa, T; Ohashi, T; Shiba, H; Uwagawa, T; Yanaga, K1
Emoto, S; Hirano, K; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Yamaguchi, H; Yamamoto, N1
Aichler, M; Baumgart, A; Blechert, B; Bruchertseifer, F; Essler, M; Feuchtinger, A; Gaertner, FC; Gilbertz, KP; Li, Z; Morgenstern, A; Seidl, C; Senekowitsch-Schmidtke, R; Vallon, M; Walch, AK1
Emoto, S; Hidemura, A; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H1
Armstrong, DK; DiSilvestro, PA; Fracasso, PM; Gould, N; Mannel, RS; Sill, MW; Thaker, PH; Waggoner, SE; Walker, JL; Yamada, SD1
Boaz, M; Golan, A; Levy, T; Menczer, J; Shem, EB; Weiser, R1
Lowe, MP; Schwartzberg, LS; Stepanski, EJ; Tillmanns, TD; Walker, MS1
Furukawa, H; Imamoto, H; Imano, M; Inoue, K; Itoh, T; Kato, H; Nishida, S; Nishikawa, M; Okuno, K; Peng, YF; Satou, T; Shinkai, M; Shiozaki, H; Takeyama, Y; Tsubaki, M; Yasuda, A; Yasuda, T1
Chiba, Y; Furukawa, H; Imamoto, H; Imano, M; Itoh, T; Kato, H; Nishida, S; Okuno, K; Peng, YF; Satou, T; Shinkai, M; Shiozaki, H; Takeyama, Y; Tsubaki, M; Yasuda, A; Yasuda, T1
Butler-Manuel, S; Essapen, S; Larbi, E; Madhuri, K; Michael, A; Tailor, A1
Alexander, HR; Alimchandani, M; Avital, I; Bartlett, DL; Beresnev, T; Eberhardt, JS; Hassan, R; Hughes, MS; Kalina, P; Kammula, US; Libutti, SK; Pandalai, P; Phan, GQ; Pingpank, JF; Quezado, M; Royal, RE; Rudloff, U; Schaub, NP; Stojadinovic, A1
Amano, R; Hirakawa, K; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Noda, E; Ohira, M; Sakurai, K; Sawada, T; Tanaka, H1
Kondo, J; Nagashima, Y; Nakamura, M; Nishimura, T; Okada, T; Sakata, K1
Fujiwara, T; Kagawa, S; Kishimoto, H; Kono, A; Nishizaki, M; Oiwa, M; Uno, F1
Antsaklis, A; Bamia, C; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Kakoyianni, K; Kostouros, E; Rodolakis, A; Thomakos, N; Vlahos, G; Zagouri, F1
Chu, P; Ghatage, P; Glaze, S; Nation, J; Nelson, G; Teitelbaum, L1
Lu, XY; Wang, ML; Wang, X; Yang, JF; Yu, HG; Zhou, LY1
Alessandroni, P; Catalano, G; Catalano, V; Fedeli, A; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Testa, E1
Ficorella, C; Marchetti, P; Narducci, F; Paris, I; Porzio, G; Ricevuto, E1
Fujimura, T; Fushida, S; Kinami, S; Miwa, K; Miyamoto, K; Nao, F; Ninomiya, I; Nishimura, G; Ohta, T; Yokogawa, K1
Fujimura, T; Furui, N; Fushida, S; Kinami, S; Miwa, K; Miyamoto, K; Ninomiya, I; Nishimura, G; Ohta, T; Yokogawa, K1
Moritake, T; Ogura, H; Terauchi, F; Yamamoto, Y1
Alvarez, AA; Berchuck, A; Carney, ME; Clarke-Pearson, DL; Havrilesky, LJ; Lancaster, JM; Rodriguez, GC; Sayer, RA; Soper, JT1
Cho, H; Imada, T; Kanari, M; Kobayashi, O; Motohashi, H; Sairenji, M; Sano, H; Tsuburaya, A1
Beijnen, JH; de Bree, E; Georgoulias, V; Michalakis, J; Romanos, J; Rosing, H; Tsiftsis, DD1
Ball, HG; Blessing, JA; DeGeest, K; Hoffman, J; Moore, DH; Rose, PG; Warshal, D1
Calderisi, MD; Corona, F; De Petris, L; Di Placido, M; Longo, F; Malizia, A; Marenga, G; Mongardini, M; Patrizi, V; Priore, FM; Schillaci, F; Scirocchi, R; Stagnitti, F; Tiberi, R1
Alberts, DS; Glass, T; Goodwin, JW; Hatch, KD; Markman, M; Smith, HO; Taylor, SA; Weiss, GR1
Marchettini, P; Mohamed, F; Stuart, OA; Sugarbaker, PH; Yoo, D1
Ishiguro, M; Kudoh, H; Murakami, S; Naka, T; Nishidoi, H; Shibata, S; Taniguchi, K; Yamaguchi, Y; Yurugi, E1
Alberts, D; Alvarez, RD; Copeland, LJ; Jiang, C; Liu, PY; Markman, M; Monk, B; Wilczynski, S1
Kinoshita, H; Kitaura, T; Nakae, S; Onoyama, H; Sainoh, K; Saitoh, Y; Shiroiwa, H; Sugihara, S; Takahashi, T; Takao, S; Toyota, J; Urakawa, T; Yamamoto, M1
Aikou, T; Arima, H; Hamada, N; Hokita, S; Ishigami, S; Maeda, S; Miyazono, F; Natsugoe, S; Takao, S; Takatori, H1
Gruenigen, VE; McElroy, TM; Waggoner, SE1
Aihara, T; Fukunaga, M; Kim, T; Kittaka, N; Kozuma, Y; Miki, H; Ozato, H; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N; Wada, H1
Boggess, JF; Boruta, DM; Fowler, WC; Gehrig, PA; Van Le, L; Walton, LA1
Alexander, HR; Bartlett, DL; Beresnev, TH; Feldman, AL; Kleiner, DE; Libutti, SK; Liewehr, DJ; Mavroukakis, SM; Pingpank, JF; Steinberg, SM1
Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K1
Chiba, F; Esato, K; Ikeda, Y; Jinbo, M; Kamei, T; Kurata, S; Mochizuki, K; Moriuchi, H; Nakafuji, Y; Nakayasu, K; Nawata, S; Oka, K; Suto, R; Zempo, N1
Imazu, H; Matsubara, T; Nakamura, Y; Ochiai, M; Sakai, W; Sakurai, Y; Tonomura, S; Yoshida, I1
Endo, Y; Hamada, A; Hikita, H; Kanai, M; Matsubayashi, Y; Miura, K; Nishikawa, H; Ochi, J; Oe, K; Ogasawara, M; Tada, E; Takeda, Y; Torii, A; Yamakawa, M1
Bookman, MA; Herzog, TJ; Look, KY; Rocereto, T; Schol, J; Vinters, J1
Belinson, J; Escobar, PF; Markman, M; Rose, P; Webster, K; Zanotti, K1
Abraham, R; Cronk, M; Perrin, L1
Balat, O1
A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R1
Ho, ES; Hung, MJ; Hwang, SF; Ke, YM; Liu, FS; Lu, CH1
Asmar, L; Bailey, CL; Gordon, AN; Messing, MJ; Pippitt, CH; Savage, J; Street, DG; Young, JA1
Birk, CL; Brown, JV; Goldstein, BH; Graham, C; Mattison, J; Micha, JP; Rettenmaier, MA1
Belinson, J; Markman, M1
Beatty, B; Cooper, K; Eltabbakh, GH; Morgan, A; Mount, SL; Simmons-Arnold, L1
Camatte, S; Castaigne, D; Dubernard, G; Duvillard, P; Fourchotte, V; Lhommé, C; Morice, P; Pautier, P; Pomel, C; Rey, A; Thoury, A1
Aghajanian, C; Anderson, S; Brown, JV; Dizon, D; Dupont, J; Eisenfeld, AJ; Jacobs, A; Mehdi, A; Peters, WA; Rivkin, S; Sabbatini, P; Spriggs, D1
Atkinson, R; Coleman, R; Gabra, H; Gordon, A; Hay, A; Jayson, GC; Kaye, SB; Parkin, D; Paul, J; Vasey, PA1
Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Nagahama, T; Oobu, M; Takashima, I1
Fujitani, K; Hirao, M; Tsujinaka, T1
Ebisui, C; Fujimoto, T; Fukuchi, N; Hasuike, Y; Hayashi, N; Izawa, H; Sakita, I; Souma, I; Yoshida, T1
Hayashidani, Y; Morifuji, M; Murakami, Y; Sasaki, M; Sueda, T; Toge, K; Yokoyama, Y1
Fusco, N; Rose, PG; Smrekar, M1
Miyade, Y; Ninomiya, M; Ohtani, S; Shimizu, Y; Sugiyama, S2
Cathomas, R; Gregory, K; Lowndes, S; Rogerson, M1
Camatte, S; Castaigne, D; Dubernard, G; Duvillard, P; Lhommé, C; Morice, P; Pautier, P; Rey, A1
Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R1
Aoki, Y; Fukada, T; Horiguchi, K; Kobayashi, J; Kobayashi, N; Miyazaki, M; Morishima, Y; Nakano, M; Shiramatsu, K; Suzuki, I; Tazawa, Y; Toyoda, Y; Yamamoto, K; Yokoyama, K1
Akanuma, M; Hata, Y; Kuriyama, H; Nonaka, T; Sawatari, T; Tsuboi, H1
Iwabuchi, S; Kashiwagi, H; Takahashi, N; Yamazaki, Y; Yanaga, K1
Gao, YN; Li, WF; Liu, JX; Tang, WS; Wang, W1
Kietpeerakool, C; Srisomboon, J; Suprasert, P1
Asai, S; Dokoh, J; Ishikawa, M; Komiyama, S; Mikami, M; Tsuji, H1
Fujiwara, M; Hibi, K; Kodera, Y; Koike, M; Nakanishi, H; Nakao, A; Ohashi, N; Tatematsu, M; Yokoyama, H1
Bidus, MA; Elkas, JC; Kyser, K; Rodriguez, M; Rose, GS1
Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Yano, S1
Kobayashi, O; Tsuburaya, A; Yoshikawa, T1
Aratake, K; Itabashi, M; Kameoka, S; Mitsuhashi, M; Ogawa, S; Seshimo, A; Shirotani, N1
Carneiro, F; Lima, J; Lopes, JM; Magro, F; Pereira, P; Saraiva, A; Sarmento, C; Tavarela-Veloso, F; Teixeira, A1
Fujio, N; Fukuda, Y; Ihara, T; Koyama, I; Osugi, H; Takatori, H; Tsukazaki, T; Tsukazaki, Y1
Banba, T; Hatakeyama, K; Kanda, T; Kosugi, S; Ohashi, M; Tanabe, T; Yajima, K1
Ami, K; Andou, M; Ganno, H; Ichikawa, S; Ito, T; Kimu, K; Kobo, T; Nagahama, T; Nawa, K; Ohbu, M; Takaba, E; Yamauchi, A1
Blessing, J; Connor, J; Hanjani, P; Markman, M; Rubin, SC; Waggoner, S1
Bang, YJ; Choi, IS; Heo, DS; Im, SA; Kim, DW; Kim, JH; Kim, NK; Kim, TY; Lee, JS; Lee, KW; Na, Ii; Oh, DY; Shin, H; Song, EK; Yun, T1
Armstrong, DK; Baergen, R; Bundy, B; Burger, RA; Copeland, LJ; Huang, HQ; Lele, S; Walker, JL; Wenzel, L1
Imada, T; Kunisaki, C; Ohshima, T; Ohtsuka, Y; Sato, T; Yamada, R1
Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y1
Aihara, T; Kim, C; Miki, H; Nakata, K; Ohzato, H; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N1
Boku, N; Fukutomi, A; Hironaka, S; Onozawa, Y; Yoshino, T; Zenda, S1
Chetrit, A; Golan, A; Levy, T; Menczer, J; Sadetzki, S1
Fujioka, T; Hirashima, Y; Kagawa, K; Kitajima, K; Kumamoto, T; Murakami, K; Noguchi, T; Sugi, S1
Beijnen, JH; de Bree, E; Georgoulias, V; Michalakis, J; Relakis, K; Romanos, J; Rosing, H; Theodoropoulos, PA; Tsiftsis, DD1
Stuart, OA; Sugarbaker, PH; Yan, TD; Yoo, D1
Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM1
Buhl, A; Chalas, E; DiSilvestro, PA; Fisher, M; Pearl, ML; Valea, FA1
Kanamaru, T; Tanaka, K; Yamamoto, M1
Higashimoto, M; Maeda, S; Maemura, M; Nagata, K; Noguchi, T; Noma, H; Ogura, O; Takebayashi, Y1
Asami, A; Baba, H; Hayashi, N; Okamoto, N; Takeshima, K; Yamafuji, K1
Hayashi, T; Murayama, Y; Shimizu, H; Watanabe, N; Yoshizawa, M1
Fusco, N; Greer, BE; Horowitz, IR; Markman, M; Rose, PG1
Honda, I; Kato, T; Kobayashi, D; Mori, M1
Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Koutsoukou, V; Papadimitriou, CA1
Collado, MV; García Villanueva, A; Pérez de Oteyza, J; Rojo, R; Ruiz-Tovar, J1
Hirakawa, K; Inoue, T; Kim, T; Kimura, K; Muguruma, K; Ohira, M; Sawada, T; Toyokawa, T; Yamashita, Y; Yashiro, M1
Itoi, K; Mizuno, Y; Nishitai, R; Okamoto, S; Shinohara, H; Shirakata, Y; Taki, Y; Yamagami, K; Yamamoto, M1
Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M1
Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Niwano, M; Ogasahara, K; Okabe, M; Paku, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y1
Alvarez, J; Campaña, O; Lamas, M; Lorenzo, D; Pérez, J; Rodríguez, MJ; Veiras, S1
Ichikawa, K; Okuda, N; Takahashi, K; Yagi, Y1
Kawaguchi, A; Yamaguchi, S; Yoshida, K1
Corrado, G; Samaritani, R; Sbiroli, C; Vizza, E1
Black, D; Fransi, S; Jacques, T; Links, M; Morris, DL; Saunders, V; Yan, TD1
Horiba, K; Ishikawa, N; Kanazawa, Y; Katsuta, M; Koizumi, M; Kudoh, H; Ohkawa, K; Seya, T; Shinji, S; Shirakawa, T; Tajiri, T; Tanaka, N; Yamada, T; Yamashita, K; Yokoi, K; Yoshioka, M1
Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E1
Byrd, L; Clamp, A; Hasan, J; Jayson, GC; Thistlethwaite, FC; Ton, C1
Goshima, F; Kasuya, H; Kodera, Y; Nakao, A; Nishiyama, Y; Shimoyama, S; Teshigahara, O1
Arakawa, T; Fujii, K; Kaneda, K; Kawamura, C; Kayo, S; Mizuyama, Y; Nakagawa, H; Ueda, Y; Uno, H1
Fujimoto, M; Takeda, Y; Takeuchi, K; Tsujino, T; Yoshida, S1
Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamaguchi, K; Yamamitsu, S1
Boggess, JF; Brady, MF; Burger, RA; Clarke-Pearson, DL; Hanly, M; Lee, RB; Mannel, R; Spriggs, DR; Vaccarello, L1
Aydin, Y; Cicin, I; Eralp, Y; Ozluk, Y; Saip, P; Selam, M; Topuz, E; Topuz, S1
Hribaschek, A; Lippert, H; Meyer, F; Pross, M; Ridwelski, K; Schneider-Stock, R1
du Bois, A; Harter, P; Hilpert, F; Pfisterer, J1
Akiyama, J; Hayashi, Y; Iwashita, R; Kobayakawa, M; Masaki, N; Nagaoki, Y; Nagata, N; Nozaki, Y; Oshima, T; Sako, A; Sakurai, T; Tamegai, Y; Uemura, N; Umeda, N; Watanabe, M; Yago, Y1
Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N1
Furukawa, N; Haruta, S; Kanayama, S; Kawaguchi, R; Kitanaka, T; Kobayashi, H; Naruse, K; Oi, H; Sado, T; Sakata, M; Yamada, Y; Yoshida, S1
Tohya, T; Ujioka, T; Yamaguchi, M1
Beijnen, JH; Daskalakis, M; de Bree, E; Filis, D; Kalbakis, K; Melisssourgaki, M; Pilatou, M; Romanos, J; Rosing, H; Sanidas, E; Taflampas, P; Tsiftsis, DD1
Fukuda, H; Kamura, T; Konishi, I; Matsumoto, K; Onda, T; Sato, A; Shibata, T; Yoshikawa, H1
Abushahin, F; Belinson, J; Fader, AN; Gibbons, H; Markman, M; Rose, P; Starks, D; von Gruenigen, V1
Barbachano, Y; Gore, M; Hook, J; Kaye, SB; Linch, M; Stavridi, F1
Fujitani, K; Furukawa, H; Goto, M; Imamoto, H; Imamura, H; Imano, M; Ishida, H; Kimura, Y; Narahara, H; Shimokawa, T; Takiuchi, H1
Alberts, DS; Alvarez, RD; Bidzinski, M; Bradford, WZ; Clouser, MC; Johnson, G; Kardatzke, DR; Kirn, DH; Loutit, J; Markman, M; Marth, C1
Iwata, S; Katoh, H; Kitaoka, A; Masumoto, H; Ohtsuka, K; Yamaki, S1
Hayashi, S; Karaki, H; Sugano, I; Sugimoto, K; Suzuki, H; Takayanagi, H; Yamamori, H; Yamamoto, K1
Ishida, T; Kameyama, T; Matsuyama, A; Okamoto, M; Okazaki, J; Tsutsui, S; Utsunomiya, T; Yamamoto, M1
Akrivos, T; Dertimas, V; Iavazzo, C; Kalinoglou, N; Katsoulis, M; Vorgias, G1
Bajorin, DF; Bosl, GJ; Fischer, P; Hutter, HS; Lyn, P; Motzer, RJ; Scher, HI; Schwartz, LH1
Donner, LR; Kavanagh, JJ; Kudelka, AP; Mante, R; Silva, E; Wilailak, S1
Jenkins, JJ; Mandrell, BN; Pratt, CB; Smiley, LM; Wall, JE1
D'Incalci, M; Giavazzi, R; Lucchini, V; Nicoletti, MI1
Abbott, BJ; D'Incalci, M; Giavazzi, R; Lucchini, V; Massazza, G; Nicoletti, MI1
Francis, P; Hakes, T; Hoskins, W; Markman, M; Rowinsky, E; Schneider, J1
Almadrones, L; Barakat, R; Curtin, J; Hakes, T; Hoskins, W; Markman, M1
Aikins, JK; Menzin, AW; Rubin, SC; Wheeler, JE1
Sharma, A; Sharma, US; Straubinger, RM1
Schrijvers, D; van Dam, P; van Oosterom, A1
Edwards, CL; Herrada, J; Kavanagh, JJ; Kudelka, AP; Shin, DM; Tornos, C; Verschraegen, CF1
Burt, HM; Davis, NL; Demetrick, JS; Hunter, WL; Liggins, RT; Machan, L1
Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K5
Blumenson, LE; Eltabbakh, GH; Hempling, RE; Piver, MS; Recio, FO1
Fluellen, L; Fusco, N; Rodriguez, M; Rose, PG1
Belinson, J; Fluellen, L; Fusco, N; Horowitz, IR; Jones, E; Kennedy, A; Kulp, B; Markman, M; McGuire, WP; Peterson, G; Rose, PG; Webster, K1
Brady, MF; Hanjani, P; Markman, M; Rubin, SC; Spirtos, NM1
Belinson, J; Hurteau, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Sutton, G; Webster, K1
Belinson, JL; Kennedy, AW; Kulp, B; Markman, M; Peterson, G; Rybicki, LA; Webster, KD1
Eltabbakh, GH; Hempling, RE; Intengen, ME; Piver, MS; Recio, FO1
Cohen, Y; Horowitz, J; Meirovitz, M; Piura, B1
Ghamande, SA; Piver, MS1
Atkinson, EN; Burke, TW; Gershenson, DM; Lee, JJ; Levenback, C; Morris, M; Silva, EG; Thall, PF; Wharton, JT; Wolf, J1
Atkinson, EN; Guedes, Ed; Kavanagh, JJ; Kudelka, AP; Nelson-Taylor, T; Rogers, R; Sittisomwong, T; Steger, M; Verschraegen, CF; Vincent, M1
Fowler, JM; Greer, BE; Horowitz, IR; McGuire, WP; Rodriguez, M; Rose, PG; Waggoner, S1
Baronius, W; Bokemeyer, C; Clemens, M; Haag, C; Hartmann, JT; Hempel, V; Kanz, L; Kollmannsberger, C; Lingenfelser, T; Quietzsch, D; Schroeder, M1
Belinson, JL; Kennedy, AW; Markman, M; Webster, KD; Zanotti, KM1
Allen, D; Davison, J; Gates, P; Neesham, D; Planner, R; Prince, HM; Quinn, M; Rischin, D1
Markman, M1
Piura, B; Rabinovich, A; Yanai-Inbar, I1
Berkowitz, RS; Campos, SM; Cook, S; Fuller, AF; Goodman, A; MacNeill, KM; Matulonis, UA; Penson, RT; Seiden, MV; Supko, JG1
Kairi-Vasilatou, E; Koutselini, HA; Lazaris, AC; Papayannopoulou, A; Thomopoulou, G1
Elit, L; Finn, M; Hirte, H; Kwon, JS; Mazurka, J; Moens, F; Trim, K1
Fujiyoshi, K; Harada, C; Ishimatsu, J; Kamura, T; Kawagoe, H; Kawata, T; Nishio, S; Sugiyama, T; Tsunawaki, A1
Buekers, T; Buller, RE; Horowitz, JA; Karlan, BY; Kreienberg, R; Pegram, M; Petrauskas, S; Runnebaum, IB; Shahin, M; Slamon, D1
Barakat, R; Curtin, J; Hakes, T; Jones, W; Lewis, JL; Markman, M; Phillips, M; Reichman, B; Rowinsky, E; Rubin, S1

Reviews

14 review(s) available for paclitaxel and Peritoneal Carcinomatosis

ArticleYear
Optimizing regional chemotherapy for epithelial ovarian cancer.
    The journal of obstetrics and gynaecology research, 2022, Volume: 48, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pemetrexed; Peritoneal Neoplasms

2022
[Malignant epithelial ovarian cancer: Role of intra peritoneal chemotherapy and hyperthermic intra peritoneal chemotherapy (HIPEC): Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian can
    Gynecologie, obstetrique, fertilite & senologie, 2019, Volume: 47, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Fallopian Tube Neoplasms; Female; France; Humans; Hyperthermia, Induced; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Societies, Medical

2019
Treatment strategies for gastric cancer patients with peritoneal metastasis.
    Surgery today, 2014, Volume: 44, Issue:3

    Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Clinical Trials, Phase II as Topic; Epithelial Cell Adhesion Molecule; Humans; Infusions, Parenteral; Molecular Targeted Therapy; Paclitaxel; Peritoneal Neoplasms; Prognosis; Receptor, ErbB-2; Silicates; Stomach Neoplasms; Survival Rate; Titanium

2014
Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2013, Volume: 27, Issue:4

    Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Evidence-Based Medicine; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A

2013
Dose-dense approaches to ovarian cancer treatment.
    Current treatment options in oncology, 2015, Volume: 16, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis

2015
Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.
    The AAPS journal, 2015, Volume: 17, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Carriers; Drug Design; Humans; Injections, Intraperitoneal; Microspheres; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Polymers

2015
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
    Annales de pathologie, 2015, Volume: 35, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Combined Modality Therapy; Cystadenofibroma; Diagnosis, Differential; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Paclitaxel; Pemetrexed; Peritoneal Neoplasms

2015
[Ramucirumab - a new anticancer agent].
    Orvosi hetilap, 2016, Volume: 157, Issue:40

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease-Free Survival; Gastrointestinal Neoplasms; Humans; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Stomach Neoplasms

2016
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, Volume: 43, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Doxorubicin; Hyperthermia, Induced; Infusions, Parenteral; Mesothelioma; Paclitaxel; Pemetrexed; Perioperative Period; Peritoneal Neoplasms; Survival Rate; Time Factors

2017
Pseudomyxoma Peritonei arising from a mucinous borderline ovarian tumour: Case report and literature review.
    The Australian & New Zealand journal of obstetrics & gynaecology, 2010, Volume: 50, Issue:4

    Topics: Antineoplastic Agents; Appendix; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Mucinous; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pseudomyxoma Peritonei

2010
Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.
    International journal of molecular sciences, 2011, Jan-31, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Carcinoma; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Versicans

2011
[A case of malignant peritoneal mesothelioma successfully treated with systemic chemothrapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2012, Volume: 109, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Pemetrexed; Peritoneal Neoplasms

2012
Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2006, Volume: 32, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Taxoids

2006
Comprehensive management of diffuse malignant peritoneal mesothelioma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2006, Volume: 32, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Humans; Hyperthermia, Induced; Mesothelioma; Mitomycin; Paclitaxel; Patient Selection; Peritoneal Neoplasms; Survival Analysis

2006

Trials

145 trial(s) available for paclitaxel and Peritoneal Carcinomatosis

ArticleYear
Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.
    Cancer medicine, 2021, Volume: 10, Issue:21

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Risk Assessment; Risk Factors; Stomach Neoplasms; Survival Analysis

2021
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
    Gynecologic oncology, 2022, Volume: 164, Issue:2

    Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asian; Bevacizumab; Black or African American; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Ethnicity; Fallopian Tube Neoplasms; Female; Hispanic or Latino; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; White People

2022
Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
    Future oncology (London, England), 2022, Volume: 18, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gastrectomy; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms; Tegafur; Young Adult

2022
A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis.
    Future oncology (London, England), 2022, Volume: 18, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms

2022
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).
    Trials, 2022, Feb-05, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms

2022
Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO.
    BMJ open, 2022, 06-22, Volume: 12, Issue:6

    Topics: Adult; Humans; Mesothelioma, Malignant; Paclitaxel; Peritoneal Neoplasms; Prospective Studies

2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 02-01, Volume: 41, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Duration of Therapy; Female; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2023
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma.
    Journal of gynecologic oncology, 2023, Volume: 34, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies

2023
Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial.
    BMC cancer, 2023, Mar-04, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Esophagogastric Junction; Humans; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Quality of Life

2023
Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study.
    International journal of colorectal disease, 2023, Jun-20, Volume: 38, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Humans; Multicenter Studies as Topic; Paclitaxel; Peritoneal Neoplasms

2023
INTRAPERITONEAL CHEMOTHERAPY FOR GASTRIC CANCER WITH PERITONEAL CARCINOMATOSIS: STUDY PROTOCOL OF A PHASE II TRIAL.
    Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery, 2023, Volume: 36

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms; Young Adult

2023
Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
    Oncology, 2020, Volume: 98, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome

2020
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
    Gynecologic oncology, 2020, Volume: 156, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival

2020
Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology.
    Annals of surgical oncology, 2020, Volume: 27, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Cisplatin; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; Paclitaxel; Perfusion; Peritoneal Neoplasms; Stomach Neoplasms

2020
Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate

2020
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Gynecologic oncology, 2020, Volume: 157, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Survival Analysis

2020
Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
    BMC cancer, 2020, May-06, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Young Adult

2020
Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
    Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:2

    Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate

2020
Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis.
    The British journal of surgery, 2020, Volume: 107, Issue:13

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Logistic Models; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Analysis; Treatment Outcome

2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-10, Volume: 38, Issue:32

    Topics: Adult; Aged; Benzimidazoles; Cystadenocarcinoma, Serous; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Protein Kinase Inhibitors; Topotecan; Young Adult

2020
Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
    Oncology, 2021, Volume: 99, Issue:1

    Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Myocardial Infarction; Oxaliplatin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2021
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
    Gynecologic oncology, 2021, Volume: 162, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Quinolines

2021
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult

2017
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
    American journal of clinical oncology, 2019, Volume: 42, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2019
Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019, Volume: 22, Issue:1

    Topics: Adult; Aged; Albumins; Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Proportional Hazards Models; Salvage Therapy; Stomach Neoplasms; Treatment Outcome

2019
Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
    Gynecologic oncology, 2018, Volume: 151, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2018
Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
    Anticancer research, 2018, Volume: 38, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur

2018
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
    Gynecologic oncology, 2018, Volume: 151, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Hydrazines; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2018
Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
    Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Patient Safety; Peritoneal Neoplasms; Prognosis; Young Adult

2019
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecologic oncology, 2019, Volume: 152, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyridines

2019
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
    Investigational new drugs, 2019, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Stomach Neoplasms; Survival Rate

2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate

2019
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Gynecologic oncology, 2013, Volume: 129, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2013
A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Consolidation Chemotherapy; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Severity of Illness Index; Survival Analysis

2013
A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
    Cancer, 2013, Sep-15, Volume: 119, Issue:18

    Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur

2013
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Gynecologic oncology, 2013, Volume: 131, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Observer Variation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Radiography; Single-Blind Method

2013
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models

2013
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib

2014
Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
    Oncology research and treatment, 2014, Volume: 37, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prevalence; Prognosis; Risk Factors; Survival Rate; Treatment Outcome; Turkey

2014
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult

2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:13

    Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Chorionic Gonadotropin; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; International Agencies; Lenograstim; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Precision Medicine; Prognosis; Recombinant Proteins; Survival Rate; Testicular Neoplasms; Young Adult

2014
A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Nanoparticles; Paclitaxel; Peritoneal Neoplasms

2015
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
    Gynecologic oncology, 2015, Volume: 139, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Body Mass Index; CA-125 Antigen; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Obesity; Ovarian Neoplasms; Paclitaxel; Patient Readmission; Peritoneal Neoplasms; Risk Factors; Time Factors

2015
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur

2016
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cytoreduction Surgical Procedures; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indoles; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors; Thrombocytopenia; Young Adult

2016
Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): A clinical pilot study.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2016, Volume: 32, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carbon Dioxide; Chemotherapy, Cancer, Regional Perfusion; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects

2016
Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial.
    Asia-Pacific journal of clinical oncology, 2016, Volume: 12, Issue:3

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Dexamethasone; Double-Blind Method; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2016
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Gr
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 64

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis

2016
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Young Adult

2017
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 70

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2017
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.
    Annals of surgery, 2017, Volume: 265, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Analysis; Tegafur; Treatment Outcome

2017
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jun-01, Volume: 26, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclosporins; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis

2008
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
    Gynecologic oncology, 2008, Volume: 110, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2008
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
    Gynecologic oncology, 2008, Volume: 110, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Drug Interactions; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid

2008
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Gynecologic oncology, 2008, Volume: 111, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid

2008
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
    Gynecologic oncology, 2009, Volume: 112, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Humans; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Quality of Life

2009
Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
    Gynecologic oncology, 2009, Volume: 112, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2009
Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.
    Gynecologic oncology, 2009, Volume: 113, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Peritoneal Neoplasms

2009
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Topotecan

2009
Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life

2009
Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer.
    Oncology, 2009, Volume: 76, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Tissue Distribution; Treatment Outcome

2009
Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:5

    Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate; Treatment Outcome

2009
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2010
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:9

    Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Drug Interactions; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2009
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult

2009
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
    Gynecologic oncology, 2010, Volume: 116, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gefitinib; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines

2010
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2010, Volume: 118, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Polyethylene Glycols; Recombinant Proteins

2010
Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:12

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ascites; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Quality of Life; Retrospective Studies; Treatment Failure; Treatment Outcome

2010
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
    Gynecologic oncology, 2010, Volume: 119, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Gene Amplification; Genes, erbB-1; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Young Adult

2010
A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial).
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Feasibility Studies; Humans; Infusions, Intravenous; Infusions, Parenteral; Japan; Paclitaxel; Patient Selection; Peritoneal Neoplasms; Research Design; Stomach Neoplasms

2011
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
    Gynecologic oncology, 2011, May-01, Volume: 121, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Young Adult

2011
Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study.
    The journal of medical investigation : JMI, 2011, Volume: 58, Issue:1-2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Drug Combinations; Female; Humans; Infusions, Parenteral; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2011
Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
    Oncology, 2010, Volume: 79, Issue:3-4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms; Survival Rate; Treatment Outcome

2010
Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Isoflavones; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Treatment Failure; Treatment Outcome

2011
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Sesquiterpenes; Survival Rate; Treatment Outcome

2010
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2011, Volume: 122, Issue:1

    Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2011
Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
    Gynecologic oncology, 2011, Volume: 122, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2011
Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    American journal of clinical oncology, 2011, Volume: 34, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Skin Neoplasms; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome

2011
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
    Gynecologic oncology, 2011, Volume: 123, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2011
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
    British journal of cancer, 2011, Sep-27, Volume: 105, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome

2011
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
    Gynecologic oncology, 2011, Volume: 123, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult

2011
Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2012
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncol
    Gynecologic oncology, 2012, Volume: 125, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2012
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-01, Volume: 30, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Fusion Proteins; Survival Analysis

2012
Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites.
    Anticancer research, 2011, Volume: 31, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Dose-Response Relationship, Drug; Female; Floxuridine; Humans; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Time Factors; Treatment Outcome

2011
Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, May-01, Volume: 18, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Injections, Intraperitoneal; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pemetrexed; Peritoneal Neoplasms; Prognosis; Survival Rate; Tissue Distribution

2012
Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:5

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate

2012
Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:116

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms

2012
Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Drug Administration Schedule; Eating; Feasibility Studies; Female; Fluorouracil; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms

2012
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic
    Gynecologic oncology, 2012, Volume: 127, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2012
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
    Gynecologic oncology, 2013, Volume: 128, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Treatment Outcome

2013
A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis.
    Anticancer research, 2012, Volume: 32, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Young Adult

2012
Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012, Volume: 16, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Humans; Instillation, Drug; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Stomach Neoplasms

2012
Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:10

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult

2013
Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Hydroxamic Acids; Incidence; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Vorinostat

2013
Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
    Minerva medica, 2002, Volume: 93, Issue:4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Peritoneal Neoplasms

2002
Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm.
    International journal of clinical oncology, 2002, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Cisplatin; Diaphragm; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Muscle Neoplasms; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2002
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
    Gynecologic oncology, 2003, Volume: 88, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2003
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2003, Volume: 88, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2003
Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
    Gynecologic oncology, 2003, Volume: 88, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2003
A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2003, Volume: 29, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Dialysis Solutions; Female; Humans; Hydroxyethyl Starch Derivatives; Infusions, Parenteral; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Statistics, Nonparametric

2003
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-01, Volume: 21, Issue:13

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2003
Weekly paclitaxel infusion as salvage therapy in ovarian cancer.
    Cancer investigation, 2003, Volume: 21, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Treatment Outcome

2003
Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2004, Volume: 92, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2004
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
    Gynecologic oncology, 2004, Volume: 92, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2004
Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary.
    European journal of gynaecological oncology, 2004, Volume: 25, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Salvage Therapy; Treatment Outcome

2004
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
    British journal of cancer, 2004, Aug-16, Volume: 91, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2004
Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
    Gynecologic oncology, 2004, Volume: 94, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy

2004
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gynecologic oncology, 2004, Volume: 94, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2004
Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Gynecologic oncology, 2004, Volume: 94, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects

2004
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Nov-15, Volume: 22, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid; Taxoids

2004
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Journal of the National Cancer Institute, 2004, Nov-17, Volume: 96, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Confidence Intervals; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Proportional Hazards Models; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome

2004
A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
    Gynecologic oncology, 2005, Volume: 96, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2005
Phase I study of a weekly schedule of fixed-dose paclitaxel and escalating doses of cisplatin for recurrent or unresectable gastric cancer in Japan.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Gastrectomy; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Japan; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Treatment Outcome

2005
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2006, Volume: 101, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2006
Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Vomiting, Anticipatory

2005
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Survival Analysis

2006
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
    Gynecologic oncology, 2006, Volume: 103, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2006
Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy.
    Gynecologic and obstetric investigation, 2007, Volume: 63, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Polyethylene Glycols; Survival Analysis; Treatment Outcome

2007
Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
    Gynecologic oncology, 2007, Volume: 104, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols

2007
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma.
    Gynecologic oncology, 2007, Volume: 104, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies

2007
[A phase I study of intraperitoneal plus intravenous paclitaxel against gastric cancer with peritoneal dissemination (HGCG 0301)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Female; Gastrectomy; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Thrombocytopenia

2006
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-01, Volume: 25, Issue:28

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis

2007
Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Peritoneal Neoplasms

2008
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Tegafur; Thrombocytopenia

2008
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of prog
    Gynecologic oncology, 2008, Volume: 109, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease-Free Survival; Female; Humans; Interferon-gamma; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Treatment Outcome

2008
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:11

    Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germinoma; Granulocyte Colony-Stimulating Factor; Humans; Male; Mediastinal Neoplasms; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Salvage Therapy; Testicular Neoplasms; Vaginal Neoplasms

1994
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects

1995
Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Papillary; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis

1996
Surgically documented responses to paclitaxel and cisplatin in patients with primary peritoneal carcinoma.
    Gynecologic oncology, 1996, Volume: 62, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Humans; Paclitaxel; Peritoneal Neoplasms

1996
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Treatment Failure

1998
Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:8

    Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate

1998
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
    Gynecologic oncology, 1998, Volume: 70, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carboplatin; Cisplatin; Cystadenocarcinoma, Papillary; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

1998
Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study.
    Journal of surgical oncology, 1999, Volume: 72, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Salvage Therapy; Topotecan

1999
A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Cancer, 1999, Dec-01, Volume: 86, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Melphalan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

1999
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Statistics, Nonparametric; Survival Analysis; Taxoids

2000
Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Thrombocytopenia

2000
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
    British journal of cancer, 2000, Volume: 83, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis

2000
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
    Gynecologic oncology, 2000, Volume: 78, Issue:3 Pt 1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Doxorubicin; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erythema; Fallopian Tube Neoplasms; Female; Foot Dermatoses; Hand Dermatoses; Humans; Liposomes; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Stomatitis; Stroke Volume

2000
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Gynecologic oncology, 2000, Volume: 79, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2000
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-01, Volume: 19, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2001
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Gynecologic oncology, 2001, Volume: 81, Issue:2

    Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2001
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.
    Cancer, 2001, Sep-01, Volume: 92, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Statistics, Nonparametric; Survival Rate; Topotecan

2001
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Cancer gene therapy, 2002, Volume: 9, Issue:7

    Topics: Adenoviridae; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cohort Studies; Combined Modality Therapy; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Fallopian Tube Neoplasms; Female; Genes, p53; Genetic Therapy; Humans; Mutation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tomography, X-Ray Computed; Transgenes

2002
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:9

    Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Infusions, Parenteral; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Peritoneum

1992

Other Studies

326 other study(ies) available for paclitaxel and Peritoneal Carcinomatosis

ArticleYear
Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models.
    Journal of medicinal chemistry, 2013, Sep-12, Volume: 56, Issue:17

    Topics: Antineoplastic Agents; Cell Line; Humans; Magnetic Resonance Spectroscopy; Mesothelioma; Peritoneal Neoplasms; Pyridines; Spectrophotometry, Ultraviolet

2013
Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma.
    Journal of medicinal chemistry, 2016, Aug-11, Volume: 59, Issue:15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Isoindoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Peritoneal Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured

2016
Efficacy of conversion surgery after a single intraperitoneal administration of paclitaxel and systemic chemotherapy for gastric cancer with peritoneal metastasis.
    Langenbeck's archives of surgery, 2022, Volume: 407, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms

2022
Complete metabolic response after carboplatin desensitization in Peritoneal Carcinomatosis.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:6

    Topics: Antineoplastic Agents; Carboplatin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography

2022
Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes.
    Current oncology (Toronto, Ont.), 2022, 03-10, Volume: 29, Issue:3

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Life Style; Liver Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Receptor, ErbB-2; Trastuzumab

2022
Ultra-high drug loading improves nanoparticle efficacy against peritoneal mesothelioma.
    Biomaterials, 2022, Volume: 285

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Humans; Mesothelioma; Mice; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Pharmaceutical Preparations

2022
Effects of particle size and release property of paclitaxel-loaded nanoparticles on their peritoneal retention and therapeutic efficacy against mouse malignant ascites.
    International journal of pharmaceutics, 2022, Jul-25, Volume: 623

    Topics: Animals; Ascites; Carcinoma; Cell Line, Tumor; Emulsions; Liposomes; Mice; Nanoparticles; Paclitaxel; Particle Size; Peritoneal Neoplasms; Quality of Life

2022
Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients.
    World journal of surgical oncology, 2022, Jun-29, Volume: 20, Issue:1

    Topics: Female; Humans; Ki-67 Antigen; Mesothelioma, Malignant; Paclitaxel; Pemetrexed; Peritoneal Neoplasms; Platinum; Prognosis; Retrospective Studies

2022
Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database.
    Journal of gynecologic oncology, 2022, Volume: 33, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Delivery of Health Care; Fallopian Tubes; Female; Humans; Incidence; Japan; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2022
[A Case of Sheath-Like Obstruction of the Entire Catheter in a Short Period of Time after Placement of an Intraperitoneal Access Port].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:13

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms

2022
Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research.
    Journal of controlled release : official journal of the Controlled Release Society, 2023, Volume: 361

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Colorectal Neoplasms; Combined Modality Therapy; Humans; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms; Pharmaceutical Preparations; Pharmaceutical Research; Proteomics; Tandem Mass Spectrometry

2023
Cytoreduction and Hyperthermic Intraperitoneal Paclitaxel and Cisplatin for Gastric Cancer with Peritoneal Metastasis.
    Annals of surgical oncology, 2024, Volume: 31, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Survival Rate

2024
[A Long-Term Survival Case of Gastric Cancer with Pyloric Stenosis and Peritoneum Dissemination That Received Intravenous and Intraperitoneal Paclitaxel Combined with S-1 Therapy after Bypass Surgery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Pyloric Stenosis; Stomach Neoplasms

2023
Primary peritoneal serous papillary carcinoma: a case series.
    Archives of gynecology and obstetrics, 2019, Volume: 300, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma, Papillary; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2019
Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis.
    Journal of controlled release : official journal of the Controlled Release Society, 2019, Volume: 311-312

    Topics: Adipose Tissue; Animals; Antineoplastic Agents; Bioengineering; Carboxylesterase; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Enzyme Therapy; Female; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prodrugs; Stem Cells

2019
Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
    International journal of clinical oncology, 2020, Volume: 25, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies

2020
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
    Scientific reports, 2019, 11-26, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Esophageal Neoplasms; Female; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Paclitaxel; Peritoneal Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Quinolines; Random Allocation; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays

2019
A simple method of quantifying chemotherapy-induced peripheral neuropathy using PainVision PS-2100
    Asia-Pacific journal of clinical oncology, 2020, Volume: 16, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Incidence; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Pilot Projects; Risk Assessment; Risk Factors; Skin; Young Adult

2020
Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study.
    Journal of gynecologic oncology, 2020, Volume: 31, Issue:2

    Topics: Adult; Aged; Carboplatin; Cohort Studies; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Republic of Korea; Retrospective Studies

2020
Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer.
    Anti-cancer drugs, 2020, Volume: 31, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Neutropenia; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Survival Rate

2020
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
    Cancer medicine, 2020, Volume: 9, Issue:10

    Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Female; Fluorouracil; Gemcitabine; Heterografts; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Treatment Failure; Trifluridine; Xenograft Model Antitumor Assays

2020
Efficacy of intraperitoneally administered paclitaxel for colorectal cancer with peritoneal metastases.
    International journal of colorectal disease, 2020, Volume: 35, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms

2020
Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series.
    Surgical oncology, 2020, Volume: 33

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Female; Humans; Hyperthermic Intraperitoneal Chemotherapy; Male; Mesothelioma, Malignant; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Treatment Outcome; Young Adult

2020
Safety, pharmacokinetics and tissue penetration of PIPAC paclitaxel in a swine model.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:5

    Topics: Animals; Biopsy; Disease Models, Animal; Female; Hyperthermic Intraperitoneal Chemotherapy; Paclitaxel; Peritoneal Neoplasms; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine

2021
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
    American journal of clinical oncology, 2020, Volume: 43, Issue:9

    Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross-Over Studies; Deoxycytidine; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Progression-Free Survival; Registries; Republic of Korea; Survival Rate; Treatment Outcome

2020
Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study.
    International journal of clinical oncology, 2021, Volume: 26, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome

2021
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Colonic Neoplasms; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Hyperthermic Intraperitoneal Chemotherapy; Laparoscopy; Length of Stay; Male; Mesothelioma; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm, Residual; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Registries; Severity of Illness Index; Survival Rate; Tumor Burden

2021
ASO Author Reflections: Repeated Intraperitoneal Paclitaxel with Systemic Chemotherapy as the First-Line Treatment for Peritoneal Malignancy.
    Annals of surgical oncology, 2021, Volume: 28, Issue:7

    Topics: Cytoreduction Surgical Procedures; Humans; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms

2021
[A Case of Unresectable Pancreatic Cancer with Massive Cancerous Ascites Responsive to KM-CART].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Female; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms

2021
Therapeutic efficacy of a paclitaxel-loaded nanofibrillated bacterial cellulose (PTX/NFBC) formulation in a peritoneally disseminated gastric cancer xenograft model.
    International journal of biological macromolecules, 2021, Mar-31, Volume: 174

    Topics: Animals; Bacteria; Carboxymethylcellulose Sodium; Cellulose; Culture Media; Drug Compounding; Humans; Injections, Intraperitoneal; Male; Mice; Mice, Nude; Nanofibers; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays

2021
Intraperitoneal paclitaxel for pancreatic cancer with peritoneal metastasis.
    The British journal of surgery, 2021, 01-27, Volume: 108, Issue:1

    Topics: Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum

2021
Author response to: Comment on: Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis.
    The British journal of surgery, 2021, 01-27, Volume: 108, Issue:1

    Topics: Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum

2021
Author's reply: Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis (Br J Surg 2020; 107: 1811-1817).
    The British journal of surgery, 2021, 05-27, Volume: 108, Issue:5

    Topics: Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum

2021
Comment on: Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis.
    The British journal of surgery, 2021, 05-27, Volume: 108, Issue:5

    Topics: Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum

2021
Improved prognosis of pancreatic cancer patients with peritoneal metastasis.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2021, Volume: 21, Issue:5

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum; Prognosis; Retrospective Studies

2021
[Primary Peritoneal Carcinoma with Long Term Survival-A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:6

    Topics: Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Omentum; Paclitaxel; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography

2021
Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers.
    Anticancer research, 2021, Volume: 41, Issue:8

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies

2021
Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 142

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2021
Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.
    Anticancer research, 2017, Volume: 37, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Survival Rate

2017
Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination.
    Internal medicine (Tokyo, Japan), 2017, Volume: 56, Issue:8

    Topics: Aged; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Delivery Systems; Fatal Outcome; Humans; Male; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms

2017
Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
    Annals of surgical oncology, 2017, Volume: 24, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Induction Chemotherapy; Injections, Intraperitoneal; Laparoscopy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Prognosis; Retrospective Studies; RNA, Messenger; Stomach Neoplasms; Survival Rate; Tegafur

2017
Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer.
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2017, Volume: 39, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Turkey

2017
Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.
    Japanese journal of clinical oncology, 2017, Nov-01, Volume: 47, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2017
The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies

2017
Eruptive cherry angiomas developing in a patient treated with ramucirumab.
    Acta oncologica (Stockholm, Sweden), 2018, Volume: 57, Issue:5

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Exanthema; Hemangioma; Humans; Liver Neoplasms; Male; Paclitaxel; Peritoneal Neoplasms; Ramucirumab; Stomach Neoplasms; Withholding Treatment

2018
Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, Volume: 44, Issue:2

    Topics: Antineoplastic Agents; Carcinoma; Cardiac Output; Cisplatin; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Mesothelioma; Mitomycin; Monitoring, Intraoperative; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Practice Patterns, Physicians'; Spain; Stomach Neoplasms; Surveys and Questionnaires

2018
[A Case of Gastric Cancer with Peritoneal Dissemination Effectively Treated with Ramucirumab and Paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Ramucirumab; Stomach Neoplasms

2017
[A Case of Successful Adjuvant Surgery for the Pancreas Head Cancer with Peritoneal Metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peritoneal Neoplasms

2017
Programmed 'triple-mode' anti-tumor therapy: Improving peritoneal retention, tumor penetration and activatable drug release properties for effective inhibition of peritoneal carcinomatosis.
    Biomaterials, 2018, Volume: 169

    Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female; Humans; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Peritoneal Neoplasms; Peritoneum

2018
Enzyme-Responsive Charge-Reversal Polymer-Mediated Effective Gene Therapy for Intraperitoneal Tumors.
    Biomacromolecules, 2018, 06-11, Volume: 19, Issue:6

    Topics: A549 Cells; Animals; Drug Delivery Systems; Female; Gene Transfer Techniques; Genes, Transgenic, Suicide; Genetic Therapy; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Peritoneal Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2018
Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    International journal of cancer, 2018, 11-01, Volume: 143, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Cell Proliferation; Cisplatin; Cystadenocarcinoma, Serous; Disease Progression; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2018
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
    Seminars in oncology, 2017, Volume: 44, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome

2017
Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
    Gynecologic oncology, 2018, Volume: 150, Issue:3

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Length of Stay; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Postoperative Complications; Survival Rate; Time Factors

2018
Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
    Anticancer research, 2018, Volume: 38, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur

2018
Reply to Z. Li et al.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 01-10, Volume: 37, Issue:2

    Topics: Cisplatin; Humans; Paclitaxel; Peritoneal Neoplasms

2019
PHOENIX-GC Trial: Underpowered for Significant Results?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 01-10, Volume: 37, Issue:2

    Topics: Cisplatin; Humans; Paclitaxel; Peritoneal Neoplasms

2019
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
    Journal of geriatric oncology, 2019, Volume: 10, Issue:4

    Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure

2019
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Ramucirumab; Stomach Neoplasms; Tegafur

2018
Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line.
    Pancreas, 2019, Volume: 48, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays

2019
Laparoscopic cytoreductive surgery and HIPEC is effective regarding peritoneum tissue paclitaxel distribution.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, Volume: 21, Issue:9

    Topics: Animals; Antineoplastic Agents, Phytogenic; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Hyperthermia, Induced; Laparoscopy; Lymph Node Excision; Paclitaxel; Pelvic Neoplasms; Peritoneal Neoplasms; Swine; Tissue Distribution

2019
[A Case of Robot-Assisted Conversion Surgery for Gastric Cancer with Peritoneal Dissemination That Responded to Intravenous and Intraperitoneal Paclitaxel Combined with S-1 Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Robotic Surgical Procedures; Stomach Neoplasms; Tegafur

2019
The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, Volume: 21, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Doxorubicin; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Retrospective Studies

2019
Primary peritoneal carcinosarcoma: A report of two cases.
    Taiwanese journal of obstetrics & gynecology, 2019, Volume: 58, Issue:2

    Topics: Abdominal Neoplasms; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Fatal Outcome; Female; Humans; Mixed Tumor, Mullerian; Paclitaxel; Peritoneal Neoplasms

2019
Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, e
    Journal of gynecology obstetrics and human reproduction, 2019, Volume: 48, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Fertility Preservation; France; Humans; Hyperthermia, Induced; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2019
Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.
    Journal of controlled release : official journal of the Controlled Release Society, 2019, 07-10, Volume: 305

    Topics: Absorbable Implants; Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Drug Implants; Female; Humans; Mice, Inbred C57BL; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Textiles

2019
The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Patient Safety; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome

2019
Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institut
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2019, Volume: 45, Issue:11

    Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cytoreduction Surgical Procedures; Doxorubicin; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Length of Stay; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Postoperative Complications; Progression-Free Survival; Retrospective Studies

2019
Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
    Investigational new drugs, 2020, Volume: 38, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome

2020
Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
    Journal of surgical oncology, 2019, Volume: 120, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies

2019
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.
    Nature reviews. Cancer, 2013, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Biomarkers, Tumor; Carboplatin; Drainage; Female; Humans; Ovarian Neoplasms; Paclitaxel; Paracentesis; Peritoneal Neoplasms; Peritoneum; Prognosis; Translational Research, Biomedical

2013
Localized toxic erythema of chemotherapy during treatment with paclitaxel.
    International journal of dermatology, 2014, Volume: 53, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Erythema; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2014
Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.
    American journal of obstetrics and gynecology, 2013, Volume: 208, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Schedule; Drug Tolerance; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome

2013
A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA).
    Anticancer research, 2013, Volume: 33, Issue:7

    Topics: Adenocarcinoma, Scirrhous; Adult; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Dichloroacetic Acid; Docetaxel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hyperthermia, Induced; Irinotecan; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Photosensitizing Agents; Prognosis; Silicates; Stomach Neoplasms; Taxoids; Tegafur; Titanium

2013
[Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Tegafur; Time Factors

2013
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
    Annals of surgical oncology, 2014, Volume: 21, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate; Tegafur

2014
Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Gynecologic oncology, 2013, Volume: 131, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Treatment Outcome

2013
Weekly paclitaxel as second-line chemotherapy in Japanese patients with advanced gastric cancer.
    Anticancer research, 2013, Volume: 33, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Ascites; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Treatment Outcome

2013
Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
    Anti-cancer drugs, 2014, Volume: 25, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Folic Acid; Folic Acid Transporters; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols

2014
[A case of rectal stenosis due to peritoneal dissemination from gastric cancer that was treated with chemoradiation therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemoradiotherapy; Constriction, Pathologic; Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Rectal Diseases; Stomach Neoplasms; Tegafur

2013
[A case of unresectable gastric cancer in a patient who maintained a good quality of life with multidisciplinary treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Brain Neoplasms; Combined Modality Therapy; Fatal Outcome; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Pyloric Stenosis; Quality of Life; Stomach Neoplasms

2013
[Repeated occlusion of the intraperitoneal access port for intraperitoneal chemotherapy in a patient with gastric cancer with peritoneal dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Cavity; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Vascular Access Devices

2013
In vivo optical pathology of paclitaxel efficacy on the peritoneal metastatic xenograft model of gastric cancer using two-photon laser scanning microscopy.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2015, Volume: 18, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Green Fluorescent Proteins; Humans; Luminescent Proteins; Mice, Nude; Mice, Transgenic; Microscopy, Confocal; Paclitaxel; Peritoneal Neoplasms; Red Fluorescent Protein; Stomach Neoplasms; Xenograft Model Antitumor Assays

2015
[A case of peritoneal carcinomatosis due to recurrence of primary adenocarcinoma of the ureter treated with weekly paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Fatal Outcome; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Recurrence; Urologic Neoplasms

2014
Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.
    Chemotherapy, 2013, Volume: 59, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Outpatients; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome

2013
Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.
    Journal of controlled release : official journal of the Controlled Release Society, 2014, Mar-28, Volume: 178

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Inhibitor of Apoptosis Proteins; Liposomes; Mice; Mice, Nude; Paclitaxel; Peritoneal Neoplasms; RNA, Small Interfering; Survivin; Transfection; Xenograft Model Antitumor Assays

2014
Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:3

    Topics: Animals; Cell Line, Tumor; Female; Humans; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tissue Distribution; Xenograft Model Antitumor Assays

2014
Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs.
    Archives of gynecology and obstetrics, 2014, Volume: 290, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2014
Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO2 recirculation system.
    Surgery, 2014, Volume: 155, Issue:4

    Topics: Abdomen; Animals; Antineoplastic Agents; Blood Gas Analysis; Body Temperature; Carbon Dioxide; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Disease Models, Animal; Female; Hemodynamics; Hyperthermia, Induced; Infusions, Parenteral; Paclitaxel; Peritoneal Neoplasms; Swine; Treatment Outcome

2014
Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.
    Gynecologic oncology, 2014, Volume: 133, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models; Treatment Outcome

2014
Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Survivin; Tumor Suppressor Protein p53

2014
[A case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome

2014
A model based analysis of IPEC dosing of paclitaxel in rats.
    Pharmaceutical research, 2014, Volume: 31, Issue:10

    Topics: Absorption, Physiological; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chemotherapy, Cancer, Regional Perfusion; Computer Simulation; Dose-Response Relationship, Drug; Female; Humans; Hyperthermia, Induced; Models, Biological; Nonlinear Dynamics; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats, Nude; Xenograft Model Antitumor Assays

2014
Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
    Oncology reports, 2014, Volume: 32, Issue:1

    Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Xenograft Model Antitumor Assays

2014
[A case of gastric adenosquamous carcinoma with peritoneal dissemination in which treatment with S-1 plus paclitaxel therapy resulted in improved long-term survival].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors

2014
The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
    Annals of surgical oncology, 2015, Volume: 22, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate

2015
Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
    Annals of surgical oncology, 2015, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytodiagnosis; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur

2015
Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC.
    Annals of surgical oncology, 2015, Volume: 22, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carboplatin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Inflammation Mediators; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate

2015
Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Colonic Neoplasms; Combined Modality Therapy; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair Enzymes; Drug Evaluation, Preclinical; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Injections, Intraperitoneal; Lead Radioisotopes; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Paclitaxel; Peritoneal Neoplasms; Radioimmunotherapy; Trastuzumab; Xenograft Model Antitumor Assays

2014
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
    Yonsei medical journal, 2014, Volume: 55, Issue:6

    Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids

2014
Comment on: "Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO₂".
    Surgery, 2015, Volume: 157, Issue:1

    Topics: Abdomen; Animals; Antineoplastic Agents; Carbon Dioxide; Chemotherapy, Cancer, Regional Perfusion; Female; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms

2015
Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.
    British journal of cancer, 2015, Jan-20, Volume: 112, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Cisplatin; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Peritoneum

2015
Reply to Comment on: "Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO₂".
    Surgery, 2015, Volume: 157, Issue:1

    Topics: Abdomen; Animals; Antineoplastic Agents; Carbon Dioxide; Chemotherapy, Cancer, Regional Perfusion; Female; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms

2015
Prolonged response to aflibercept in ovarian cancer relapse: a case report.
    Tumori, 2015, Mar-20, Volume: 101, Issue:1

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Lymphatic Metastasis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A

2015
[A case of primary peritoneal carcinoma successfully treated using Paclitaxel and Carboplatin chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Carboplatin; Female; Humans; Membrane Proteins; Paclitaxel; Peritoneal Neoplasms

2014
[A recurrent gastric cancer with peritoneal metastasis 15 years after distal gastrectomy successfully treated with S-1 and weekly intravenous and intraperitoneal injections of Paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Combinations; Female; Gastrectomy; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms; Tegafur; Time Factors

2015
Primary peritoneal cancer: study of 14 cases and comparison with epithelial ovarian cancer.
    European journal of gynaecological oncology, 2015, Volume: 36, Issue:1

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate

2015
Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Blood Proteins; Body Temperature; Cell-Free System; Drug Combinations; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Laparoscopy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Platelet Count; Retrospective Studies; Second-Look Surgery; Serum Albumin; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome

2015
Utility of delayed reading of intradermal test in carboplatin-induced drug hypersensitivity.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2015, Volume: 114, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Skin Tests

2015
Primary peritoneal serous psammocarcinoma: a case report.
    Journal of gastrointestinal and liver diseases : JGLD, 2015, Volume: 24, Issue:2

    Topics: Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Calcinosis; Carboplatin; Chemotherapy, Adjuvant; Colectomy; Cytoreduction Surgical Procedures; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Peritoneal Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2015
Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
    Journal of controlled release : official journal of the Controlled Release Society, 2015, Oct-28, Volume: 216

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Gene Silencing; Genetic Therapy; Humans; Inhibitor of Apoptosis Proteins; Injections, Intravenous; Lipids; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; RNA, Neoplasm; RNA, Small Interfering; Survivin; Transfection; Xenograft Model Antitumor Assays

2015
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Gynecologic oncology, 2015, Volume: 139, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome

2015
Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin.
    Clinical and experimental medicine, 2016, Volume: 16, Issue:4

    Topics: Animals; Apoptosis; Ascites; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Drug Therapy, Combination; Erythromycin; Humans; Mice; Orosomucoid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Xenograft Model Antitumor Assays

2016
[Clinical efficacy of paclitaxel combined with S-1 in the prevention and treatment of gastric cancer with peritoneal metastasis].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2015, Volume: 18, Issue:10

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome

2015
[Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer].
    Voprosy onkologii, 2015, Volume: 61, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Melphalan; Mitomycin; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Wistar; Triazines

2015
Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:2

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cytoreduction Surgical Procedures; Female; Hospitals, High-Volume; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult

2016
Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer.
    British journal of cancer, 2016, Jan-19, Volume: 114, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Esophagogastric Junction; Female; Humans; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome

2016
A patient with gastric cancer with peritoneal carcinomatosis treated with intraperitoneal chemotherapy who survived more than 5 years receiving repeated laparoscopic examinations: a case report.
    Journal of medical case reports, 2016, Jan-19, Volume: 10

    Topics: Antineoplastic Agents, Phytogenic; Asian People; Carcinoma; Drug Administration Schedule; Female; Gastrectomy; Humans; Injections, Intraperitoneal; Laparoscopy; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Treatment Outcome

2016
[A Case of Long-Term Survival of a Patient with Gastric Cancer with Peritoneal Dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors

2015
[A Case of Double Cancers of the Stomach and Endometrium with Peritoneal Metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Combinations; Endometrial Neoplasms; Female; Gastrectomy; Humans; Hysterectomy; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Tegafur

2015
[Introduction of Chemotherapy for Advanced Gastric Cancer Showing Oncologic Emergency Caused by Peritoneal Dissemination--Report of Tow Cases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Ileus; Jaundice, Obstructive; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2015
[A Case of Long-Term Survival in a Patient with Small Intestinal Adenocarcinoma with Peritoneal Dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Floxuridine; Humans; Intestinal Obstruction; Jejunal Neoplasms; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Time Factors

2016
Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2016, Volume: 32, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Young Adult

2016
Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:4

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Humans; Injections, Intraperitoneal; Mice; Paclitaxel; Peritoneal Neoplasms; Polymers; Tissue Distribution; Xenograft Model Antitumor Assays

2016
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2016, Volume: 32, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; China; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Docetaxel; Female; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Middle Aged; Mitomycin; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids

2016
[A Patient with Gastric Cancer with Peritoneal Dissemination Who Survived for Five Years after Sequential Chemotherapy with S-1 Followed by Paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Fatal Outcome; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2016
Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
    Oncotarget, 2016, Jul-26, Volume: 7, Issue:30

    Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Immunohistochemistry; Inhibitory Concentration 50; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Pyrazoles; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Somatomedins; Triazines; Xenograft Model Antitumor Assays

2016
Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
    Chinese journal of cancer, 2016, May-09, Volume: 35

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Propensity Score; Prospective Studies; Treatment Outcome

2016
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience.
    European journal of gynaecological oncology, 2016, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cohort Studies; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Sarcoma; Survival Rate; Treatment Outcome; Uterine Neoplasms; Young Adult

2016
Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2016, Volume: 104

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Hydrogels; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Polymers; Tissue Distribution

2016
Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
    Gynecologic oncology, 2016, Volume: 142, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Guideline Adherence; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids

2016
Proof-of-Concept of Polymeric Sol-Gels in Multi-Drug Delivery and Intraoperative Image-Guided Surgery for Peritoneal Ovarian Cancer.
    Pharmaceutical research, 2016, Volume: 33, Issue:9

    Topics: Animals; Drug Carriers; Drug Delivery Systems; Female; Hydrogels; Injections, Intraperitoneal; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyesters; Polyethylene Glycols; Polymers; Sirolimus; Surgery, Computer-Assisted

2016
Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma.
    Biomaterials, 2016, Volume: 102

    Topics: Animals; Antineoplastic Agents, Phytogenic; Autophagosomes; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; Mesothelioma; Mice, Nude; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Peritoneum

2016
Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Analysis

2016
Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference?
    Surgical oncology, 2016, Volume: 25, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate

2016
Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2016
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2017, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Infusions, Parenteral; Male; Middle Aged; Oxaloacetates; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Stomach Neoplasms; Survival Rate

2017
Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017, Volume: 20, Issue:Suppl 1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur

2017
[A Case of Primary Peritoneal Cancer Successfully Treated with Debulking Surgery and Postoperative Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2016
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
    Gynecologic oncology, 2017, Volume: 145, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult

2017
A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma.
    PloS one, 2017, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Disease Models, Animal; Esophageal Neoplasms; Heterografts; Mice; Neoplasm Transplantation; Paclitaxel; Peritoneal Neoplasms

2017
High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.
    Pharmaceutical research, 2017, Volume: 34, Issue:6

    Topics: Abdominal Wall; Animals; Antineoplastic Agents, Phytogenic; Drug Compounding; Drug Design; Female; Hyperthermia, Induced; Injections, Intraperitoneal; Nanoparticles; Paclitaxel; Particle Size; Peritoneal Absorption; Peritoneal Neoplasms; Permeability; Rabbits; Surface Properties; Tissue Distribution

2017
[A case of gastric cancer with peritoneal dissemination responding to combination chemotherapy with oral fluoropyrimidine and weekly paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:6

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed

2008
A three-year survivor case of gastric cancer with peritoneal dissemination--an outpatient with second-line weekly paclitaxel.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Female; Humans; Middle Aged; Outpatients; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed

2008
Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Combined Modality Therapy; Female; Humans; Immunoglobulin G; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Peritoneal Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Trastuzumab; Xenograft Model Antitumor Assays

2008
Intra-thoracic cytoreduction of stage IV peritoneal malignancy: a case series.
    Gynecologic oncology, 2008, Volume: 111, Issue:3

    Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Diaphragm; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms

2008
Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle--a new strategy against peritoneal dissemination of gastric cancer.
    Cancer letters, 2008, Dec-18, Volume: 272, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Female; Humans; Hyaluronic Acid; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Peritoneal Neoplasms; Pharmaceutical Vehicles; Stomach Neoplasms

2008
Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer.
    International journal of cancer, 2008, Dec-01, Volume: 123, Issue:11

    Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Female; Genetic Therapy; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Paclitaxel; Peritoneal Neoplasms; RNA, Small Interfering; Stomach Neoplasms; Survival Rate; Time Factors; Transcription Factor RelA; Xenograft Model Antitumor Assays

2008
In vitro cytotoxicity of paclitaxel/beta-cyclodextrin complexes for HIPEC.
    International journal of pharmaceutics, 2009, Feb-09, Volume: 367, Issue:1-2

    Topics: Animals; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Caco-2 Cells; Cell Culture Techniques; Cell Survival; Combined Modality Therapy; Drug Carriers; Excipients; Hot Temperature; Humans; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms; Rats

2009
[Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zhonghua fu chan ke za zhi, 2008, Volume: 43, Issue:11

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Retrospective Studies; Survival Analysis; Treatment Outcome

2008
Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer.
    International journal of clinical oncology, 2008, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome

2008
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Gynecologic oncology, 2009, Volume: 113, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Outpatients; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Retrospective Studies

2009
Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.
    World journal of surgical oncology, 2009, Feb-09, Volume: 7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Cystadenocarcinoma, Serous; Feasibility Studies; Female; Humans; Injections, Intraperitoneal; Intraoperative Care; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Treatment Outcome

2009
Primary peritoneal carcinoma in a young woman with suspected endometriosis.
    Fertility and sterility, 2009, Volume: 92, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy; Carboplatin; Diagnosis, Differential; Endometriosis; Female; Fertility; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Lymph Nodes; Omentum; Oocytes; Ovary; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Young Adult

2009
[Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Tegafur

2009
Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
    Gynecologic oncology, 2009, Volume: 114, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2009
Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer.
    Cancer science, 2009, Volume: 100, Issue:10

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Carriers; Female; Humans; Injections, Intraperitoneal; Methacrylates; Mice; Mice, Nude; Paclitaxel; Peritoneal Neoplasms; Phosphorylcholine; Stomach Neoplasms; Tissue Distribution; Xenograft Model Antitumor Assays

2009
Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
    Cancer letters, 2010, Jan-28, Volume: 287, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Ascites; Biological Transport; Carcinoma, Hepatocellular; Cell Line, Tumor; Docetaxel; Female; Glycerol; Injections, Intraperitoneal; Liver Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polysorbates; Rats; Surface-Active Agents; Taxoids; Tissue Distribution

2010
[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur

2009
Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.
    Endocrine-related cancer, 2009, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Estrogen Receptor alpha; Female; Gene Expression Profiling; Humans; Middle Aged; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate

2009
The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Gynecologic oncology, 2009, Volume: 115, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2009
[A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Gastroscopy; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Radiography; Stomach Neoplasms; Tegafur; Treatment Outcome

2009
Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma.
    Gynecologic oncology, 2010, Volume: 116, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Databases, Factual; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epithelial Cells; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2010
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
    International journal of clinical oncology, 2009, Volume: 14, Issue:5

    Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome

2009
Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Blotting, Western; Cell Line, Tumor; Coloring Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Iodine Radioisotopes; Mice; Mice, Inbred BALB C; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tetrazolium Salts; Thiazoles; Tissue Distribution; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2010
[Outcome of therapy for type 4 gastric cancer with peritoneal metastasis--diagnosis by laparoscopy and effect of chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Laparoscopy; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome

2009
[A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Infusions, Parenteral; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2009
[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2010
Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.
    Oncology, 2010, Volume: 78, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Tegafur; Tomography, X-Ray Computed

2010
[Strategy of treatment for gastric cancer with peritoneal metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:3

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2010
Scleroderma induced by paclitaxel.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Female; Genetic Predisposition to Disease; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Scleroderma, Localized; Sex Factors; Time Factors

2010
Intraperitoneal chemotherapy for advanced ovarian and peritoneal cancers in patients following interval debulking surgery or primary cytoreductive surgery: Tom Baker Cancer Centre experience from 2006 to 2009.
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2010, Volume: 32, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2010
Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2010, Volume: 13, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur

2010
The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Female; Humans; Hydrogels; Luciferases, Firefly; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Peritoneal Neoplasms; Polymers; Stomach Neoplasms; Temperature; Time Factors; Transfection; Xenograft Model Antitumor Assays

2012
Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma.
    The British journal of surgery, 2011, Volume: 98, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Female; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Length of Stay; Male; Mesothelioma, Cystic; Paclitaxel; Peritoneal Neoplasms

2011
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
    American journal of clinical oncology, 2011, Volume: 34, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome

2011
A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Japan; Ovarian Neoplasms; Paclitaxel; Patient Selection; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Research Design

2011
Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules.
    Cancer science, 2011, Volume: 102, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Female; Humans; Injections, Intraperitoneal; Liver; Methacrylates; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Phosphorylcholine; Solubility; Tissue Distribution

2011
The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis.
    Biomaterials, 2011, Volume: 32, Issue:3

    Topics: Albumins; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Survival; Female; Humans; Mesothelioma; Mice; Mice, Nude; Microscopy, Confocal; Microscopy, Electron, Scanning; Paclitaxel; Peritoneal Neoplasms

2011
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome

2011
Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
    Oncology reports, 2011, Volume: 25, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Immunoenzyme Techniques; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Transforming Growth Factor beta1

2011
Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:4

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Availability; Carboplatin; Disease Models, Animal; Female; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Xenograft Model Antitumor Assays

2011
[A case of gastric cancer with peritoneal dissemination successfully treated by S-1/paclitaxel combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastroscopy; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed

2011
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome

2012
Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.
    Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Endothelin Receptor Antagonists; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pyrimidines; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011
Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model.
    Pharmaceutical research, 2011, Volume: 28, Issue:7

    Topics: Animals; Antineoplastic Agents; beta-Cyclodextrins; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Disease Models, Animal; Hyperthermia, Induced; Injections, Intraperitoneal; Magnetic Resonance Imaging; Paclitaxel; Peritoneal Neoplasms; Positron-Emission Tomography; Rats; Time Factors; Tumor Burden

2011
Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms.
    American journal of surgery, 2011, Volume: 202, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Databases, Factual; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Mitomycin; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Peritoneum

2011
Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2011, Volume: 13, Issue:4

    Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Humans; Hyperthermia, Induced; Mitomycin; Paclitaxel; Peritoneal Neoplasms; Pseudomyxoma Peritonei

2011
A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Survival Rate; Treatment Outcome

2010
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
    Gynecologic oncology, 2011, Volume: 122, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan

2011
Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Prospective Studies; Treatment Outcome

2011
Aggressive ovarian psammocarcinoma: a case report.
    European journal of gynaecological oncology, 2011, Volume: 32, Issue:2

    Topics: Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Serous; Female; Humans; Laparotomy; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2011
Peritoneal relapse of testicular seminomatous germ cell tumor treated successfully with salvage chemotherapy and autologous stem cell transplantation.
    Clinical genitourinary cancer, 2011, Volume: 9, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Ifosfamide; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Seminoma; Stem Cell Transplantation; Testicular Neoplasms; Transplantation, Autologous

2011
[A case of peritoneal serous papillary carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Serous Membrane; Tomography Scanners, X-Ray Computed

2011
Safety of intraperitoneal administration of paclitaxel after gastrectomy with en-bloc D2 lymph node dissection.
    Journal of surgical oncology, 2012, Volume: 105, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Female; Follow-Up Studies; Gastrectomy; Humans; Injections, Intraperitoneal; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Postoperative Complications; Prospective Studies; Safety; Stomach Neoplasms; Survival Rate; Treatment Outcome

2012
Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis.
    Biomaterials, 2011, Volume: 32, Issue:33

    Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Combined Modality Therapy; Female; Folic Acid; Humans; Mice; Mice, Nude; Microscopy, Fluorescence; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2011
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
    Anticancer research, 2011, Volume: 31, Issue:7

    Topics: Adjuvants, Immunologic; Biomarkers, Tumor; CA-125 Antigen; Cancer Vaccines; Carboplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystadenocarcinoma, Serous; Docetaxel; Female; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunotherapy, Active; Membrane Proteins; Middle Aged; Omentum; Ovarian Neoplasms; Paclitaxel; Peptide Fragments; Peritoneal Neoplasms; Taxoids; Tumor Burden; Vaccines, Subunit; WT1 Proteins

2011
Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
    European journal of gynaecological oncology, 2011, Volume: 32, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2011
Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects.
    Radiology, 2012, Volume: 263, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Choline; Contrast Media; Diffusion Magnetic Resonance Imaging; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Spectroscopy; Middle Aged; Organometallic Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed

2012
Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma.
    Gynecologic and obstetric investigation, 2012, Volume: 73, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2012
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate

2012
Prognosis of primary peritoneal carcinoma: effect of cytoreductive surgery combined with neoadjuvant chemotherapy after laparoscopic diagnosis and evaluation: a multi-center trial.
    European journal of gynaecological oncology, 2012, Volume: 33, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Kaplan-Meier Estimate; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Ovariectomy; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salpingectomy

2012
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Gynecologic oncology, 2012, Volume: 125, Issue:3

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult

2012
[Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Quality of Life; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed

2012
Malignant peritoneal mesothelioma in a 16-year-old girl: presentation of a rare disease.
    Klinische Padiatrie, 2012, Volume: 224, Issue:3

    Topics: Abdominal Pain; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Diagnosis, Differential; Female; Humans; Mesothelioma; Paclitaxel; Peritoneal Neoplasms; Rare Diseases

2012
Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites.
    Nanoscale, 2012, May-21, Volume: 4, Issue:10

    Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Erythrocytes; Fluorouracil; Hydrogel, Polyethylene Glycol Dimethacrylate; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Peritoneal Neoplasms; Polyesters; Polyethylene Glycols; Rabbits; Temperature

2012
Development of a nanocrystalline Paclitaxel formulation for HIPEC treatment.
    Pharmaceutical research, 2012, Volume: 29, Issue:9

    Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Crystallization; Female; Microscopy, Electron; Nanotechnology; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats

2012
Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
    Gynecologic oncology, 2012, Volume: 126, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Pelvis; Peritoneal Neoplasms; Proportional Hazards Models; Retrospective Studies

2012
Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Gynecologic oncology, 2012, Volume: 127, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2012
[A long-surviving patient with unresectable advanced gastric cancer treated with S-1 and biweekly paclitaxel combination chemotherapy as second-line treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fatal Outcome; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Tegafur

2012
Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice.
    Digestive diseases and sciences, 2013, Volume: 58, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzamidines; Caspase 3; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation; Guanidines; Humans; I-kappa B Proteins; Male; Mice; Mice, Nude; Neoplasms, Experimental; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Peritoneal Neoplasms; Poly(ADP-ribose) Polymerases; Stomach Neoplasms

2013
Role of intervention for biliary and gastric/intestinal obstruction in gastric cancer with peritoneal metastasis.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Drainage; Drug Combinations; Endoscopy, Digestive System; Female; Humans; Intestinal Obstruction; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stents; Stomach Neoplasms; Tegafur

2012
Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest.
    European journal of nuclear medicine and molecular imaging, 2012, Volume: 39, Issue:12

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Division; Cell Line, Tumor; Chemoradiotherapy; G2 Phase Cell Cycle Checkpoints; HEK293 Cells; HMGN2 Protein; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Organometallic Compounds; Paclitaxel; Peritoneal Neoplasms; Protein Structure, Tertiary; Radiopharmaceuticals; Treatment Outcome

2012
Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheter-Related Infections; Catheters, Indwelling; Cisplatin; Feasibility Studies; Female; Humans; Infusions, Parenteral; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; Vascular Access Devices

2012
Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:8

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate

2012
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2013, Volume: 25, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2013
A novel nomogram for peritoneal mesothelioma predicts survival.
    Annals of surgical oncology, 2013, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; Bayes Theorem; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Nomograms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate; Young Adult

2013
[A case of far-advanced gastric cancer successfully treated with S-1/paclitaxel/krestin immunochemotherapy, followed by curative resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Immunotherapy; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Proteoglycans; Stomach Neoplasms; Tegafur

2012
[A case report of complete response by weekly paclitaxel and 5'-DFUR combination chemotherapy for recurrenced gastric cancer with peritoneal dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Floxuridine; Gastrectomy; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms

2012
[Stent placement using a double-balloon endoscope for malignant duodenal obstruction with Roux-en-Y Anastomosis-a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12

    Topics: Aged; Anastomosis, Roux-en-Y; Combined Modality Therapy; Double-Balloon Enteroscopy; Duodenal Obstruction; Fatal Outcome; Gastrectomy; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Stents; Stomach Neoplasms

2012
Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Oncology, 2013, Volume: 84, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate

2013
Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative.
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2013, Volume: 35, Issue:1

    Topics: Alberta; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Survival Rate

2013
Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin.
    European journal of gynaecological oncology, 2002, Volume: 23, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cisplatin; Diagnosis, Differential; Drug Hypersensitivity; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Skin Tests

2002
[Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Mitomycin; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Vindesine

2002
[Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12

    Topics: Adult; Aged; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms

2002
[A case of metastatic gastric cancer responding to weekly administration of paclitaxel as a second-line therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Gastrectomy; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms

2003
Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer.
    Anti-cancer drugs, 2003, Volume: 14, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Carcinoma; Combined Modality Therapy; Docetaxel; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Intraoperative Care; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids; Tissue Distribution

2003
[Peritoneal papillary serous carcinoma: clinical report].
    Il Giornale di chirurgia, 2002, Volume: 23, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Papillary; Fatal Outcome; Female; Humans; Paclitaxel; Peritoneal Neoplasms

2002
[A case of advanced gastric cancer with peritoneal metastases responding to bi-weekly paclitaxel therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tomography, X-Ray Computed

2003
[A patient with peritoneal metastasis from gastric cancer who responded to weekly chemotherapy with paclitaxel on the third line and could take meal].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Silicates; Stomach Neoplasms; Titanium

2003
[A case of advanced type 4 gastric cancer with peritonitis dissemination, navel metastasis effectively treated with combined chemotherapy of biweekly paclitaxel (TXL) and TS-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colonic Diseases; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Pyridines; Splenectomy; Stomach Neoplasms; Tegafur; Umbilicus

2003
A case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity.
    Gynecologic oncology, 2003, Volume: 91, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms

2003
[A case of gastric cancer with peritoneal dissemination which showed the intraperitoneal CR by administrating TS-1 orally and paclitaxel intraperitoneally].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Injections, Intraperitoneal; Male; Oxonic Acid; Paclitaxel; Peritoneal Cavity; Peritoneal Neoplasms; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur

2003
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-15, Volume: 21, Issue:24

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models; Survival Analysis; Treatment Outcome

2003
Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
    Gynecologic oncology, 2003, Volume: 91, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

2003
[Two cases of non-curatively resected scirrhous gastric cancer that responded well to weekly paclitaxel therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:13

    Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Postoperative Care; Quality of Life; Retroperitoneal Neoplasms; Stomach Neoplasms

2003
Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2003, Volume: 6, Issue:4

    Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Constriction, Pathologic; Drug Administration Schedule; Female; Gastrectomy; Humans; Paclitaxel; Peritoneal Neoplasms; Rectal Diseases; Recurrence; Stomach Neoplasms; Time Factors; Treatment Outcome

2003
[A case of effective weekly paclitaxel administration for primary lesion of schirrous gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:1

    Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms

2004
Case report of a generalized seizure related to Paclitaxel infusion.
    Journal of the National Cancer Institute, 2004, Mar-17, Volume: 96, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Papillary; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Seizures

2004
A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Second-Look Surgery; Treatment Outcome

2005
Factors associated with cytoreducibility among women with ovarian carcinoma.
    Gynecologic oncology, 2004, Volume: 95, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2004
Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2004, Volume: 30, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Treatment Outcome

2004
[A case of gastric cancer with peritoneal dissemination which shows a remarkable efficacy by a weekly administration of paclitaxel intraperitoneally].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Drug Administration Schedule; Female; Humans; Injections, Intraperitoneal; Neoplasm Seeding; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Treatment Outcome

2004
[Safety of intraperitoneal chemotherapy with paclitaxel in gastric cancer patients with peritoneal dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Aged; Antineoplastic Agents, Phytogenic; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasm Seeding; Paclitaxel; Peritoneal Neoplasms; Safety; Stomach Neoplasms

2004
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Hydronephrosis; Lymph Node Excision; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Pyridines; Stents; Stomach Neoplasms; Tegafur

2004
[A case of recurrent gastric cancer with malignant ascites responding dramatically to chemotherapy with paclitaxel infused systemically and intraperitoneally].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:12

    Topics: Aged; Antineoplastic Agents, Phytogenic; Ascites; Drug Administration Schedule; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms

2004
[A case report of recurrent gastric cancer in which combination chemotherapy with paclitaxel and 5-fluorouracil made for successful biliary stenting and improvement in QOL].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biliary Tract; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Humans; Infusions, Intravenous; Infusions, Parenteral; Jaundice, Obstructive; Lymph Node Excision; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stents; Stomach Neoplasms

2005
Primary peritoneal carcinoma with acute renal failure: successful treatment with chemotherapy.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2005, Volume: 17, Issue:1

    Topics: Acute Kidney Injury; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Female; Humans; Paclitaxel; Paraneoplastic Syndromes; Peritoneal Neoplasms; Renal Dialysis; Treatment Outcome

2005
Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma.
    Gynecologic oncology, 2005, Volume: 97, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carcinoma, Papillary; Combined Modality Therapy; Cystadenocarcinoma, Serous; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2005
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3

    Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Administration Schedule; Female; Floxuridine; Humans; Hysterotomy; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Nitriles; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Triazoles

2005
[A case of non-curatively resected scirrhous gastric cancer successfully treated over 2 years with weekly administration of paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3

    Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Female; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Splenectomy; Stomach Neoplasms; Survivors

2005
[A case of advanced gastric cancer with peritoneal dissemination effectively treated by combined chemotherapy of paclitaxel (TXL) and TS-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur

2005
[Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids

2005
Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Sectional Studies; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2005
A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer.
    European journal of gynaecological oncology, 2005, Volume: 26, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Platinum Compounds; Taxoids; Treatment Outcome

2005
Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice.
    International journal of oncology, 2005, Volume: 27, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Green Fluorescent Proteins; Humans; Immunohistochemistry; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Peritoneal Neoplasms; Plasmids; Platelet Endothelial Cell Adhesion Molecule-1; Stomach Neoplasms; Survival Analysis; Survival Rate; Transfection; Treatment Outcome; Xenograft Model Antitumor Assays

2005
Spontaneous pregnancy following cytoreduction with peritonectomy and hyperthermic intraperitoneal chemotherapy.
    Gynecologic oncology, 2006, Volume: 100, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fertility; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Mesothelioma; Paclitaxel; Peritoneal Neoplasms; Pregnancy

2006
[Peritoneal dissemination of scirrhous type 4 gastric cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:10

    Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Etoposide; Female; Gastrectomy; Humans; Immunotherapy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur

2005
[Treatment strategy for primary gastric cancer with peritoneal dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Methotrexate; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur

2005
[Prediction and treatment of peritoneal dissemination in gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Humans; Ileus; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Cavity; Peritoneal Lavage; Peritoneal Neoplasms; Predictive Value of Tests; Prognosis; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur

2005
Colon stenosis in a patient with ulcerative colitis as a manifestation of mixed müllerian tumor of the peritoneum.
    Scandinavian journal of gastroenterology, 2005, Volume: 40, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colitis, Ulcerative; Colon; Constriction, Pathologic; Endoscopy, Gastrointestinal; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Paclitaxel; Peritoneal Neoplasms

2005
[A case of advanced gastric cancer with direct invasion of the transverse colon responding to paclitaxel/5'-DFUR combined therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:12

    Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Colon, Transverse; Colonic Neoplasms; Drug Administration Schedule; Floxuridine; Humans; Ileus; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms

2005
[Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur

2005
[A case of ascities decrease in malignant peritoneal mesothelioma by weekly intra-peritoneal administration of cisplatin and paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Humans; Infusions, Parenteral; Male; Mesothelioma; Middle Aged; Paclitaxel; Peritoneal Neoplasms

2005
[Low-dose weekly paclitaxel therapy proved useful for a case of recurrent gastric cancer with clinically latent hepatic cirrhosis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:1

    Topics: Aged; Anastomosis, Roux-en-Y; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrectomy; Humans; Liver Cirrhosis; Male; Neoplasm Invasiveness; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms

2006
[A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Male; Mitomycin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survivors; Tegafur

2006
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated over 1 year 8 months with combined chemotherapy of paclitaxel and TS-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur

2006
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2006, Volume: 9, Issue:1

    Topics: Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate

2006
Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.
    Gynecologic oncology, 2006, Volume: 103, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Physical Examination

2006
[Successful bi-weekly paclitaxel treatment of an AFP-producing gastric cancer patient with peritoneal dissemination and multiple liver metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:4

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur

2006
[A case of long-term survival of gastric cancer with peritoneal metastasis effectively treated by TS-1 and paclitaxel (PTX) combination therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Sigmoid Diseases; Stomach Neoplasms; Tegafur

2006
[A case of malignant peritoneal mesothelioma successfully treated with carboplatin and paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Mesothelioma; Paclitaxel; Peritoneal Neoplasms; Remission Induction

2006
[A long-term survival case after resection for umbilical metastasis from gastric cancer treated with weekly paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:8

    Topics: Abdominal Neoplasms; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Survivors; Umbilicus

2006
[A case of recurrent gastric cancer effectively treated by combined chemotherapy of weekly paclitaxel (PTX) and CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms

2006
[A case of advanced gastric cancer with peritoneal metastasis that responded to paclitaxel plus 5-FU therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:9

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Humans; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms

2006
Papillary serous carcinoma of peritoneum: presentation of 2 cases.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:10

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Postoperative Care; Radiography, Abdominal; Time Factors; Tomography, X-Ray Computed; Topotecan; Treatment Outcome

2006
[A case of advanced gastric cancer with malignant ascites responding to weekly paclitaxel therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:11

    Topics: Adenocarcinoma, Scirrhous; Antineoplastic Agents, Phytogenic; Ascites; Drug Administration Schedule; Female; Humans; Hydronephrosis; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms

2006
[A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13

    Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Ascites; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pylorus; Stomach Neoplasms; Tegafur

2006
[A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1

    Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms; Taxoids; Tegafur

2007
[Weekly paclitaxel therapy effective for gastric cancer with obstructive jaundice due to peritoneal dissemination--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Ascites; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Jaundice, Obstructive; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms

2007
[Anesthetic management for scheduled peritonectomy and hyperthermic intraperitoneal chemotherapy in 20 patients].
    Revista espanola de anestesiologia y reanimacion, 2006, Volume: 53, Issue:9

    Topics: Adult; Aged; Analgesia, Epidural; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intravenous; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colloids; Combined Modality Therapy; Crystalloid Solutions; Diuretics; Erythrocyte Transfusion; Female; Fever; Fluid Therapy; Fluorouracil; Humans; Hyperthermia, Induced; Hypotension; Intraoperative Complications; Isotonic Solutions; Male; Middle Aged; Mitomycin; Monitoring, Intraoperative; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Plasma; Postoperative Complications; Prospective Studies; Vasoconstrictor Agents

2006
[A case of recurrent gastric cancer with peritoneal dissemination responding to doxifluridine/paclitaxel combination chemotherapy as third-line treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Floxuridine; Gastrectomy; Humans; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Splenectomy; Stomach Neoplasms

2007
[A case of scirrhous gastric cancer with peritoneal metastases successfully treated by combined chemotherapy of biweekly paclitaxel and TS-1 followed by curative resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:4

    Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Routes; Gastrectomy; Humans; Lymph Node Excision; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Silicates; Stomach Neoplasms; Titanium

2007
Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
    BMC cancer, 2007, Apr-15, Volume: 7

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Colostomy; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Epoetin Alfa; Erythropoietin; Fatal Outcome; Female; Follow-Up Studies; Hemorrhage; Humans; Intestinal Obstruction; Karnofsky Performance Status; Laparotomy; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Peritoneal Neoplasms; Recombinant Proteins; Salvage Therapy; Topotecan; Urinary Bladder Neoplasms; Vitamins

2007
Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy Center.
    Annals of surgical oncology, 2007, Volume: 14, Issue:8

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Australia; Female; Fluorouracil; General Surgery; Humans; Infusions, Parenteral; Intraoperative Care; Learning; Male; Middle Aged; Morbidity; Mortality; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Time Factors; Treatment Outcome

2007
[Three advanced gastric cancer patients successfully treated by combination therapy of paclitaxel and cisplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms

2007
[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Fluorouracil; Gastroscopy; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Pyloric Stenosis; Quality of Life; Stomach Neoplasms; Survivors

2007
Weekly paclitaxel in the treatment of recurrent ovarian carcinoma.
    European journal of gynaecological oncology, 2007, Volume: 28, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome

2007
Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.
    Hepato-gastroenterology, 2007, Volume: 54, Issue:76

    Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Genetic Vectors; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Paclitaxel; Peritoneal Neoplasms; Simplexvirus

2007
[Case of advanced gastric cancer successfully treated with chemotherapy of weekly paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Cisplatin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2007
Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel.
    European journal of gynaecological oncology, 2007, Volume: 28, Issue:4

    Topics: Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Female; Humans; Infusions, Parenteral; Mesothelioma; Paclitaxel; Peritoneal Neoplasms; Radiotherapy, Adjuvant

2007
[The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms

2007
Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Gynecologic oncology, 2008, Volume: 108, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate

2008
Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis.
    Chemotherapy, 2007, Volume: 53, Issue:6

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Injections, Intraperitoneal; Injections, Intravenous; Liver Neoplasms, Experimental; Male; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Inbred ACI; Rats, Inbred Strains

2007
[Peritoneal carcinomatosis in ovarian cancer. Methods and treatment results].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2007, Volume: 78, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female; Humans; Infusions, Intravenous; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Reoperation; Survival Rate

2007
[A case of recurrent gastric cancer with peritoneal dissemination--prolonging life and good QOL by chemotherapy with combined use of paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoembryonic Antigen; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Sensitivity and Specificity; Stomach Neoplasms

2007
Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2007, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Hydronephrosis; Infusions, Parenteral; Liver Neoplasms; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2007
Peritoneal disseminated recurrence and lung metastasis after surgery for stage IA uterine papillary serous carcinoma of the endometrium: a case report.
    Archives of gynecology and obstetrics, 2008, Volume: 278, Issue:3

    Topics: Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Peritoneal Neoplasms

2008
[Successful treatment of primary peritoneal carcinoma with paclitaxel and carboplatin combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Paclitaxel; Peritoneal Neoplasms

2008
Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
    Annals of surgical oncology, 2008, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Intraoperative Period; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2008
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Gynecologic oncology, 2008, Volume: 109, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome

2008
Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
    Gynecologic oncology, 2008, Volume: 109, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2008
[A case report of curative resection for gastric cancer with peritoneal dissemination successfully treated by combined chemotherapy of S-1 and paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2008
[A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2008
[A case of advanced gastric cancer with Schnitzler's metastases effectively treated by the combination of paclitaxel and S-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur

2008
Primary peritoneal serous papillary carcinoma: clinical and laboratory characteristics.
    Archives of gynecology and obstetrics, 2008, Volume: 278, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Ascites; CA-125 Antigen; Carboplatin; Cisplatin; Constipation; Cystadenocarcinoma, Serous; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Weight Gain

2008
Peritoneal papillary serous carcinoma: response to Taxol in platinum resistant disease.
    European journal of gynaecological oncology, 1995, Volume: 16, Issue:3

    Topics: Carboplatin; Cystadenocarcinoma, Papillary; Drug Resistance; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms

1995
Effectiveness of paclitaxel in treating papillary serous carcinoma of the peritoneum in an adolescent.
    American journal of obstetrics and gynecology, 1995, Volume: 172, Issue:3

    Topics: Adolescent; Cystadenocarcinoma, Papillary; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Remission Induction

1995
Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Ascites; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids; Transplantation, Heterologous

1994
Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:2

    Topics: Animals; Female; Humans; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Remission Induction

1993
Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia.
    Cancer letters, 1996, Oct-22, Volume: 107, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Carriers; Drug Screening Assays, Antitumor; Female; Leukemia P388; Life Expectancy; Liposomes; Mice; Mice, Inbred DBA; Paclitaxel; Peritoneal Neoplasms

1996
CA 125: a misleading tumor marker?
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1996, Volume: 55, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; CA-125 Antigen; Cystadenocarcinoma, Mucinous; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids

1996
Remission with carboplatin of paclitaxel resistant primary peritoneal papillary serous carcinoma: case report.
    European journal of gynaecological oncology, 1997, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Papillary; Drug Resistance; Female; Humans; Paclitaxel; Peritoneal Neoplasms

1997
The development of a novel intraperitoneal tumor-seeding prophylactic.
    American journal of surgery, 1997, Volume: 173, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Glioblastoma; Injections, Intraperitoneal; Microspheres; Neoplasm Seeding; Neoplasm Transplantation; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Wistar

1997
Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma; Cause of Death; Drug Hypersensitivity; Endometrial Neoplasms; Female; Fever; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Sepsis; Thrombocytopenia; Treatment Outcome

1997
Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
    Gynecologic oncology, 1997, Volume: 67, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Survival Rate

1997
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Treatment Outcome

1998
Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma.
    Journal of cancer research and clinical oncology, 1998, Volume: 124, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

1998
Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum.
    Gynecologic oncology, 1998, Volume: 71, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cisplatin; Cystadenocarcinoma, Papillary; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms

1998
Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma.
    Journal of surgical oncology, 1999, Volume: 70, Issue:1

    Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Combined Modality Therapy; Female; Humans; Mesothelioma; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Analysis

1999
Dermatomyositis and peritoneal papillary serous carcinoma.
    European journal of obstetrics, gynecology, and reproductive biology, 1999, Volume: 82, Issue:1

    Topics: Aged; Antineoplastic Agents, Phytogenic; Ascites; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Dermatomyositis; Female; Humans; Hysterectomy; Laparoscopy; Laparotomy; Mucin-1; Paclitaxel; Peritoneal Neoplasms; Pleural Effusion

1999
Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
    Gynecologic oncology, 2000, Volume: 79, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2000
Prolonged symptom-free survival in a patient with persistent primary peritoneal carcinoma and a rising CA-125: a note of caution.
    Gynecologic oncology, 2001, Volume: 81, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Disease-Free Survival; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests

2001
Psammomacarcinoma of the peritoneum.
    European journal of obstetrics, gynecology, and reproductive biology, 2001, Volume: 97, Issue:2

    Topics: Adnexa Uteri; Aged; Antineoplastic Agents; Ascitic Fluid; Biomarkers, Tumor; CA-125 Antigen; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma; Female; Humans; Hysterectomy; Jejunum; Omentum; Paclitaxel; Peritoneal Neoplasms; Tomography, X-Ray Computed; Ultrasonography

2001
Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
    Advances in clinical pathology : the official journal of Adriatic Society of Pathology, 2001, Volume: 5, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nucleus; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Diagnosis, Differential; Female; Humans; Mesothelioma; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms

2001
A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
    Gynecologic oncology, 2002, Volume: 84, Issue:3

    Topics: Administration, Oral; Cohort Studies; Dexamethasone; Diphenhydramine; Drug Hypersensitivity; Female; Glucocorticoids; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Injections, Intravenous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Ranitidine; Retrospective Studies

2002
[A case of extraovarian primary peritoneal carcinoma successfully treated with weekly paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2

    Topics: Acute Kidney Injury; Aged; Antineoplastic Agents, Phytogenic; Cisplatin; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Humans; Paclitaxel; Peritoneal Neoplasms

2002